<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:SKVI="http://skinvisible.com/20260930"
  xmlns:dei="http://xbrl.sec.gov/dei/2026"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:us-gaap="http://fasb.org/us-gaap/2026"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="skvi-20260930.xsd" xlink:type="simple"/>
    <context id="From2026-01-01to2026-09-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001085277</identifier>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-09-30</endDate>
        </period>
    </context>
    <context id="AsOf2026-11-06">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001085277</identifier>
        </entity>
        <period>
            <instant>2026-11-06</instant>
        </period>
    </context>
    <context id="AsOf2026-09-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001085277</identifier>
        </entity>
        <period>
            <instant>2026-09-30</instant>
        </period>
    </context>
    <context id="AsOf2025-12-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001085277</identifier>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="From2026-07-012026-09-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001085277</identifier>
        </entity>
        <period>
            <startDate>2026-07-01</startDate>
            <endDate>2026-09-30</endDate>
        </period>
    </context>
    <context id="From2025-07-012025-09-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001085277</identifier>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="From2025-01-012025-09-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001085277</identifier>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="AsOf2025-12-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001085277</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="AsOf2025-12-31_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001085277</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="AsOf2025-12-31_custom_StockPayableMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001085277</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">SKVI:StockPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="AsOf2025-12-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001085277</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="AsOf2026-03-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001085277</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="AsOf2026-03-31_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001085277</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="AsOf2026-03-31_custom_StockPayableMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001085277</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">SKVI:StockPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="AsOf2026-03-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001085277</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="AsOf2026-03-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001085277</identifier>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="AsOf2026-06-30_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001085277</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="AsOf2026-06-30_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001085277</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="AsOf2026-06-30_custom_StockPayableMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001085277</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">SKVI:StockPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="AsOf2026-06-30_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001085277</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="AsOf2026-06-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001085277</identifier>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001085277</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001085277</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_custom_StockPayableMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001085277</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">SKVI:StockPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001085277</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001085277</identifier>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2025-03-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001085277</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="AsOf2025-03-31_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001085277</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="AsOf2025-03-31_custom_StockPayableMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001085277</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">SKVI:StockPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="AsOf2025-03-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001085277</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="AsOf2025-03-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001085277</identifier>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="AsOf2025-06-30_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001085277</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="AsOf2025-06-30_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001085277</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="AsOf2025-06-30_custom_StockPayableMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001085277</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">SKVI:StockPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="AsOf2025-06-30_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001085277</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="AsOf2025-06-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001085277</identifier>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="From2026-01-012026-03-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001085277</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="From2026-01-012026-03-31_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001085277</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="From2026-01-012026-03-31_custom_StockPayableMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001085277</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">SKVI:StockPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="From2026-01-012026-03-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001085277</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="From2026-01-012026-03-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001085277</identifier>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="From2026-04-012026-06-30_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001085277</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-04-01</startDate>
            <endDate>2026-06-30</endDate>
        </period>
    </context>
    <context id="From2026-04-012026-06-30_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001085277</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-04-01</startDate>
            <endDate>2026-06-30</endDate>
        </period>
    </context>
    <context id="From2026-04-012026-06-30_custom_StockPayableMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001085277</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">SKVI:StockPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-04-01</startDate>
            <endDate>2026-06-30</endDate>
        </period>
    </context>
    <context id="From2026-04-012026-06-30_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001085277</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-04-01</startDate>
            <endDate>2026-06-30</endDate>
        </period>
    </context>
    <context id="From2026-04-012026-06-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001085277</identifier>
        </entity>
        <period>
            <startDate>2026-04-01</startDate>
            <endDate>2026-06-30</endDate>
        </period>
    </context>
    <context id="From2026-07-012026-09-30_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001085277</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-07-01</startDate>
            <endDate>2026-09-30</endDate>
        </period>
    </context>
    <context id="From2026-07-012026-09-30_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001085277</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-07-01</startDate>
            <endDate>2026-09-30</endDate>
        </period>
    </context>
    <context id="From2026-07-012026-09-30_custom_StockPayableMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001085277</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">SKVI:StockPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-07-01</startDate>
            <endDate>2026-09-30</endDate>
        </period>
    </context>
    <context id="From2026-07-012026-09-30_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001085277</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-07-01</startDate>
            <endDate>2026-09-30</endDate>
        </period>
    </context>
    <context id="From2025-01-012025-03-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001085277</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="From2025-01-012025-03-31_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001085277</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="From2025-01-012025-03-31_custom_StockPayableMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001085277</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">SKVI:StockPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="From2025-01-012025-03-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001085277</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="From2025-01-012025-03-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001085277</identifier>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="From2025-04-012025-06-30_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001085277</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-04-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="From2025-04-012025-06-30_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001085277</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-04-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="From2025-04-012025-06-30_custom_StockPayableMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001085277</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">SKVI:StockPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-04-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="From2025-04-012025-06-30_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001085277</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-04-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="From2025-04-012025-06-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001085277</identifier>
        </entity>
        <period>
            <startDate>2025-04-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="From2025-07-012025-09-30_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001085277</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="From2025-07-012025-09-30_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001085277</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="From2025-07-012025-09-30_custom_StockPayableMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001085277</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">SKVI:StockPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="From2025-07-012025-09-30_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001085277</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="AsOf2026-09-30_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001085277</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-09-30</instant>
        </period>
    </context>
    <context id="AsOf2026-09-30_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001085277</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-09-30</instant>
        </period>
    </context>
    <context id="AsOf2026-09-30_custom_StockPayableMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001085277</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">SKVI:StockPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-09-30</instant>
        </period>
    </context>
    <context id="AsOf2026-09-30_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001085277</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-09-30</instant>
        </period>
    </context>
    <context id="AsOf2025-09-30_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001085277</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="AsOf2025-09-30_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001085277</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="AsOf2025-09-30_custom_StockPayableMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001085277</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">SKVI:StockPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="AsOf2025-09-30_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001085277</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="AsOf2025-09-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001085277</identifier>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="From2001-12-062026-09-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001085277</identifier>
        </entity>
        <period>
            <startDate>2001-12-06</startDate>
            <endDate>2026-09-30</endDate>
        </period>
    </context>
    <context id="From2026-01-012026-09-30_custom_ConvertibleNotesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001085277</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">SKVI:ConvertibleNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-09-30</endDate>
        </period>
    </context>
    <context id="AsOf2023-01-31_custom_ConvertibleNotePayableJan2023Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001085277</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">SKVI:ConvertibleNotePayableJan2023Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-01-31</instant>
        </period>
    </context>
    <context id="From2023-01-312023-01-31_custom_ConvertibleNotePayableJan2023Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001085277</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">SKVI:ConvertibleNotePayableJan2023Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-31</startDate>
            <endDate>2023-01-31</endDate>
        </period>
    </context>
    <context id="AsOf2026-09-30_custom_ConvertibleNotePayableJan2023Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001085277</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">SKVI:ConvertibleNotePayableJan2023Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-09-30</instant>
        </period>
    </context>
    <context id="AsOf2026-12-31_custom_ConvertibleNotePayableJan2023Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001085277</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">SKVI:ConvertibleNotePayableJan2023Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-12-31</instant>
        </period>
    </context>
    <context id="AsOf2026-09-30_custom_RelatedPartyNotesPayableTotalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001085277</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">SKVI:RelatedPartyNotesPayableTotalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-09-30</instant>
        </period>
    </context>
    <context id="AsOf2026-12-31_custom_RelatedPartyNotesPayableTotalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001085277</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">SKVI:RelatedPartyNotesPayableTotalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-12-31</instant>
        </period>
    </context>
    <context id="AsOf2025-02-07_custom_PromissoryNotePayableFeb7Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001085277</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">SKVI:PromissoryNotePayableFeb7Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-02-07</instant>
        </period>
    </context>
    <context id="From2025-02-072025-02-07_custom_PromissoryNotePayableFeb7Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001085277</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">SKVI:PromissoryNotePayableFeb7Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-02-07</startDate>
            <endDate>2025-02-07</endDate>
        </period>
    </context>
    <context id="AsOf2026-09-30_custom_PromissoryNotePayableFeb7Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001085277</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">SKVI:PromissoryNotePayableFeb7Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-09-30</instant>
        </period>
    </context>
    <context id="AsOf2025-12-31_custom_PromissoryNotePayableFeb7Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001085277</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">SKVI:PromissoryNotePayableFeb7Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="AsOf2019-09-30_custom_ConvertibleNoteOneRenagotioatedMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001085277</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">SKVI:ConvertibleNoteOneRenagotioatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-30</instant>
        </period>
    </context>
    <context id="From2019-09-302019-09-30_custom_ConvertibleNoteOneRenagotioatedMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001085277</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">SKVI:ConvertibleNoteOneRenagotioatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-09-30</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="AsOf2026-09-30_custom_ConvertibleNoteOneRenagotioatedMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001085277</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">SKVI:ConvertibleNoteOneRenagotioatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-09-30</instant>
        </period>
    </context>
    <context id="AsOf2025-12-31_custom_ConvertibleNoteOneRenagotioatedMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001085277</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">SKVI:ConvertibleNoteOneRenagotioatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="From2026-01-012026-09-30_custom_ConvertibleNoteOneRenagotioatedMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001085277</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">SKVI:ConvertibleNoteOneRenagotioatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-09-30</endDate>
        </period>
    </context>
    <context id="AsOf2026-09-30_custom_TotalConvertibleNotesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001085277</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">SKVI:TotalConvertibleNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-09-30</instant>
        </period>
    </context>
    <context id="AsOf2025-12-31_custom_TotalConvertibleNotesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001085277</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">SKVI:TotalConvertibleNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="AsOf2026-09-30_custom_TotalConvertibleNotesCurrentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001085277</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">SKVI:TotalConvertibleNotesCurrentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-09-30</instant>
        </period>
    </context>
    <context id="AsOf2025-12-31_custom_TotalConvertibleNotesCurrentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001085277</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">SKVI:TotalConvertibleNotesCurrentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="AsOf2026-09-30_custom_TotalLongTermConvertibleNotesCurrentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001085277</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">SKVI:TotalLongTermConvertibleNotesCurrentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-09-30</instant>
        </period>
    </context>
    <context id="AsOf2025-12-31_custom_TotalLongTermConvertibleNotesCurrentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001085277</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">SKVI:TotalLongTermConvertibleNotesCurrentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="AsOf2025-12-31_custom_OriginalSharesIssuedMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001085277</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">SKVI:OriginalSharesIssuedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="From2026-01-012026-09-30_custom_OriginalSharesIssuedMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001085277</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">SKVI:OriginalSharesIssuedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-09-30</endDate>
        </period>
    </context>
    <context id="AsOf2026-09-30_custom_OriginalSharesIssuedMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001085277</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">SKVI:OriginalSharesIssuedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-09-30</instant>
        </period>
    </context>
    <context id="From2020-10-172020-10-17">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001085277</identifier>
        </entity>
        <period>
            <startDate>2020-10-17</startDate>
            <endDate>2020-10-17</endDate>
        </period>
    </context>
    <context id="From2020-10-172020-12-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001085277</identifier>
        </entity>
        <period>
            <startDate>2020-10-17</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="From2022-06-142022-06-14_custom_QuoinMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001085277</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:OtherCommitmentsAxis">SKVI:QuoinMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-06-14</startDate>
            <endDate>2022-06-14</endDate>
        </period>
    </context>
    <context id="From2020-06-012020-06-10">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001085277</identifier>
        </entity>
        <period>
            <startDate>2020-06-01</startDate>
            <endDate>2020-06-10</endDate>
        </period>
    </context>
    <unit id="USD">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="Shares">
        <measure>shares</measure>
    </unit>
    <unit id="USDPShares">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="Pure">
        <measure>pure</measure>
    </unit>
    <dei:AmendmentFlag contextRef="From2026-01-01to2026-09-30" id="Fact000003">false</dei:AmendmentFlag>
    <dei:CurrentFiscalYearEndDate contextRef="From2026-01-01to2026-09-30" id="Fact000004">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:DocumentFiscalYearFocus contextRef="From2026-01-01to2026-09-30" id="Fact000005">2026</dei:DocumentFiscalYearFocus>
    <dei:DocumentFiscalPeriodFocus contextRef="From2026-01-01to2026-09-30" id="Fact000006">Q3</dei:DocumentFiscalPeriodFocus>
    <dei:EntityCentralIndexKey contextRef="From2026-01-01to2026-09-30" id="Fact000007">0001085277</dei:EntityCentralIndexKey>
    <us-gaap:CostOfRevenue
      contextRef="From2026-07-012026-09-30"
      id="xdx2ixbrl0124"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:CostOfRevenue
      contextRef="From2025-07-012025-09-30"
      id="xdx2ixbrl0125"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:CostOfRevenue
      contextRef="From2026-01-01to2026-09-30"
      id="xdx2ixbrl0126"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:CostOfRevenue
      contextRef="From2025-01-012025-09-30"
      id="xdx2ixbrl0127"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:OtherIncome
      contextRef="From2026-07-012026-09-30"
      id="xdx2ixbrl0164"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:OtherIncome
      contextRef="From2025-07-012025-09-30"
      id="xdx2ixbrl0165"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:OtherIncome
      contextRef="From2026-01-01to2026-09-30"
      id="xdx2ixbrl0166"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2025-12-31_custom_StockPayableMember"
      id="xdx2ixbrl0196"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2026-01-012026-03-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0201"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2026-01-012026-03-31_us-gaap_AdditionalPaidInCapitalMember"
      id="xdx2ixbrl0202"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2026-01-012026-03-31_custom_StockPayableMember"
      id="xdx2ixbrl0203"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2026-01-012026-03-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0206"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2026-03-31_custom_StockPayableMember"
      id="xdx2ixbrl0210"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2026-04-012026-06-30_us-gaap_CommonStockMember"
      id="xdx2ixbrl0214"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2026-04-012026-06-30_us-gaap_AdditionalPaidInCapitalMember"
      id="xdx2ixbrl0215"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2026-04-012026-06-30_custom_StockPayableMember"
      id="xdx2ixbrl0216"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2026-04-012026-06-30_us-gaap_CommonStockMember"
      id="xdx2ixbrl0219"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2026-06-30_custom_StockPayableMember"
      id="xdx2ixbrl0223"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2026-07-012026-09-30_us-gaap_CommonStockMember"
      id="xdx2ixbrl0228"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2026-07-012026-09-30_us-gaap_AdditionalPaidInCapitalMember"
      id="xdx2ixbrl0229"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2026-07-012026-09-30_custom_StockPayableMember"
      id="xdx2ixbrl0230"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2026-07-012026-09-30_us-gaap_CommonStockMember"
      id="xdx2ixbrl0233"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2026-09-30_custom_StockPayableMember"
      id="xdx2ixbrl0237"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueOther
      contextRef="From2025-01-012025-03-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0252"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2025-01-012025-03-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0256"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2025-01-012025-03-31_us-gaap_AdditionalPaidInCapitalMember"
      id="xdx2ixbrl0257"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2025-01-012025-03-31_custom_StockPayableMember"
      id="xdx2ixbrl0258"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2025-01-012025-03-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0261"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2025-03-31_custom_StockPayableMember"
      id="xdx2ixbrl0265"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2025-04-012025-06-30_us-gaap_CommonStockMember"
      id="xdx2ixbrl0270"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2025-04-012025-06-30_us-gaap_AdditionalPaidInCapitalMember"
      id="xdx2ixbrl0271"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2025-04-012025-06-30_custom_StockPayableMember"
      id="xdx2ixbrl0272"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2025-04-012025-06-30_us-gaap_CommonStockMember"
      id="xdx2ixbrl0275"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2025-06-30_custom_StockPayableMember"
      id="xdx2ixbrl0279"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2025-07-012025-09-30_us-gaap_CommonStockMember"
      id="xdx2ixbrl0284"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2025-07-012025-09-30_us-gaap_AdditionalPaidInCapitalMember"
      id="xdx2ixbrl0285"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2025-07-012025-09-30_custom_StockPayableMember"
      id="xdx2ixbrl0286"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2025-07-012025-09-30_us-gaap_CommonStockMember"
      id="xdx2ixbrl0289"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2025-09-30_custom_StockPayableMember"
      id="xdx2ixbrl0293"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:PaymentsToAcquireProductiveAssets
      contextRef="From2026-01-01to2026-09-30"
      id="xdx2ixbrl0328"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="From2026-01-01to2026-09-30"
      id="xdx2ixbrl0331"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="From2026-01-01to2026-09-30"
      id="xdx2ixbrl0337"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ProceedsFromNotesPayable
      contextRef="From2026-01-01to2026-09-30"
      id="xdx2ixbrl0340"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:InterestPaid
      contextRef="From2026-01-01to2026-09-30"
      id="xdx2ixbrl0361"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:InterestPaid
      contextRef="From2025-01-012025-09-30"
      id="xdx2ixbrl0362"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:IncomeTaxesPaid
      contextRef="From2026-01-01to2026-09-30"
      id="xdx2ixbrl0364"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:IncomeTaxesPaid
      contextRef="From2025-01-012025-09-30"
      id="xdx2ixbrl0365"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:DebtInstrumentUnamortizedDiscount
      contextRef="AsOf2026-09-30_custom_RelatedPartyNotesPayableTotalMember"
      id="xdx2ixbrl0444"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:DebtInstrumentUnamortizedDiscount
      contextRef="AsOf2026-12-31_custom_RelatedPartyNotesPayableTotalMember"
      id="xdx2ixbrl0445"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ConvertibleLongTermNotesPayable
      contextRef="AsOf2026-09-30_custom_TotalLongTermConvertibleNotesCurrentMember"
      id="xdx2ixbrl0479"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ConvertibleLongTermNotesPayable
      contextRef="AsOf2025-12-31_custom_TotalLongTermConvertibleNotesCurrentMember"
      id="xdx2ixbrl0480"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted
      contextRef="From2026-01-012026-09-30_custom_OriginalSharesIssuedMember"
      id="xdx2ixbrl0487"
      unitRef="Shares"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="From2026-01-012026-09-30_custom_OriginalSharesIssuedMember"
      id="xdx2ixbrl0488"
      unitRef="USDPShares"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations
      contextRef="From2026-01-012026-09-30_custom_OriginalSharesIssuedMember"
      id="xdx2ixbrl0489"
      unitRef="Shares"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
      contextRef="From2026-01-012026-09-30_custom_OriginalSharesIssuedMember"
      id="xdx2ixbrl0490"
      unitRef="USDPShares"
      xsi:nil="true"/>
    <dei:DocumentType contextRef="From2026-01-01to2026-09-30" id="Fact000013">10-Q</dei:DocumentType>
    <dei:DocumentQuarterlyReport contextRef="From2026-01-01to2026-09-30" id="Fact000014">true</dei:DocumentQuarterlyReport>
    <dei:DocumentPeriodEndDate contextRef="From2026-01-01to2026-09-30" id="Fact000015">2026-09-30</dei:DocumentPeriodEndDate>
    <dei:DocumentTransitionReport contextRef="From2026-01-01to2026-09-30" id="Fact000016">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber contextRef="From2026-01-01to2026-09-30" id="Fact000017">000-25911</dei:EntityFileNumber>
    <dei:EntityRegistrantName contextRef="From2026-01-01to2026-09-30" id="Fact000018">Skinvisible, Inc.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="From2026-01-01to2026-09-30" id="Fact000019">NV</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber contextRef="From2026-01-01to2026-09-30" id="Fact000020">88-0344219</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="From2026-01-01to2026-09-30" id="Fact000021">6320 South Sandhill Road</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2 contextRef="From2026-01-01to2026-09-30" id="Fact000022">Suite 10</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown contextRef="From2026-01-01to2026-09-30" id="Fact000023">Las Vegas</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="From2026-01-01to2026-09-30" id="Fact000024">NV</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="From2026-01-01to2026-09-30" id="Fact000025">89120</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="From2026-01-01to2026-09-30" id="Fact000026">702</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="From2026-01-01to2026-09-30" id="Fact000027">433.7154</dei:LocalPhoneNumber>
    <dei:EntityCurrentReportingStatus contextRef="From2026-01-01to2026-09-30" id="Fact000028">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent contextRef="From2026-01-01to2026-09-30" id="Fact000029">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory contextRef="From2026-01-01to2026-09-30" id="Fact000030">Non-accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness contextRef="From2026-01-01to2026-09-30" id="Fact000031">true</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany contextRef="From2026-01-01to2026-09-30" id="Fact000032">false</dei:EntityEmergingGrowthCompany>
    <dei:EntityShellCompany contextRef="From2026-01-01to2026-09-30" id="Fact000033">false</dei:EntityShellCompany>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="AsOf2026-11-06"
      decimals="INF"
      id="Fact000034"
      unitRef="Shares">5403843</dei:EntityCommonStockSharesOutstanding>
    <us-gaap:Cash
      contextRef="AsOf2026-09-30"
      decimals="0"
      id="Fact000042"
      unitRef="USD">4370</us-gaap:Cash>
    <us-gaap:Cash
      contextRef="AsOf2025-12-31"
      decimals="0"
      id="Fact000043"
      unitRef="USD">2620</us-gaap:Cash>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="AsOf2026-09-30"
      decimals="0"
      id="Fact000045"
      unitRef="USD">5000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="AsOf2025-12-31"
      decimals="0"
      id="Fact000046"
      unitRef="USD">5000</us-gaap:AccountsReceivableNetCurrent>
    <SKVI:DueFromRelatedParty
      contextRef="AsOf2026-09-30"
      decimals="0"
      id="Fact000048"
      unitRef="USD">17592</SKVI:DueFromRelatedParty>
    <SKVI:DueFromRelatedParty
      contextRef="AsOf2025-12-31"
      decimals="0"
      id="Fact000049"
      unitRef="USD">17592</SKVI:DueFromRelatedParty>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="AsOf2026-09-30"
      decimals="0"
      id="Fact000051"
      unitRef="USD">4500</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="AsOf2025-12-31"
      decimals="0"
      id="Fact000052"
      unitRef="USD">2319</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="AsOf2026-09-30"
      decimals="0"
      id="Fact000054"
      unitRef="USD">31462</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="AsOf2025-12-31"
      decimals="0"
      id="Fact000055"
      unitRef="USD">27531</us-gaap:AssetsCurrent>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="AsOf2026-09-30"
      decimals="0"
      id="Fact000057"
      unitRef="USD">84849</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="AsOf2025-12-31"
      decimals="0"
      id="Fact000058"
      unitRef="USD">100036</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:Assets
      contextRef="AsOf2026-09-30"
      decimals="0"
      id="Fact000060"
      unitRef="USD">116311</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="AsOf2025-12-31"
      decimals="0"
      id="Fact000061"
      unitRef="USD">127567</us-gaap:Assets>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent
      contextRef="AsOf2026-09-30"
      decimals="0"
      id="Fact000069"
      unitRef="USD">1501666</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent
      contextRef="AsOf2025-12-31"
      decimals="0"
      id="Fact000070"
      unitRef="USD">1253669</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent>
    <us-gaap:InterestPayableCurrent
      contextRef="AsOf2026-09-30"
      decimals="0"
      id="Fact000072"
      unitRef="USD">3785404</us-gaap:InterestPayableCurrent>
    <us-gaap:InterestPayableCurrent
      contextRef="AsOf2025-12-31"
      decimals="0"
      id="Fact000073"
      unitRef="USD">3357157</us-gaap:InterestPayableCurrent>
    <us-gaap:OtherLoansPayableCurrent
      contextRef="AsOf2026-09-30"
      decimals="0"
      id="Fact000075"
      unitRef="USD">135945</us-gaap:OtherLoansPayableCurrent>
    <us-gaap:OtherLoansPayableCurrent
      contextRef="AsOf2025-12-31"
      decimals="0"
      id="Fact000076"
      unitRef="USD">45044</us-gaap:OtherLoansPayableCurrent>
    <us-gaap:LoansPayable
      contextRef="AsOf2026-09-30"
      decimals="0"
      id="Fact000078"
      unitRef="USD">10000</us-gaap:LoansPayable>
    <us-gaap:LoansPayable
      contextRef="AsOf2025-12-31"
      decimals="0"
      id="Fact000079"
      unitRef="USD">10000</us-gaap:LoansPayable>
    <us-gaap:ConvertibleLongTermNotesPayable
      contextRef="AsOf2026-09-30"
      decimals="0"
      id="Fact000081"
      unitRef="USD">352075</us-gaap:ConvertibleLongTermNotesPayable>
    <us-gaap:ConvertibleLongTermNotesPayable
      contextRef="AsOf2025-12-31"
      decimals="0"
      id="Fact000082"
      unitRef="USD">352075</us-gaap:ConvertibleLongTermNotesPayable>
    <us-gaap:LiabilitiesCurrent
      contextRef="AsOf2026-09-30"
      decimals="0"
      id="Fact000084"
      unitRef="USD">5785090</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="AsOf2025-12-31"
      decimals="0"
      id="Fact000085"
      unitRef="USD">5017945</us-gaap:LiabilitiesCurrent>
    <us-gaap:LongTermNotesAndLoans
      contextRef="AsOf2026-09-30"
      decimals="0"
      id="Fact000087"
      unitRef="USD">5372403</us-gaap:LongTermNotesAndLoans>
    <us-gaap:LongTermNotesAndLoans
      contextRef="AsOf2025-12-31"
      decimals="0"
      id="Fact000088"
      unitRef="USD">5372403</us-gaap:LongTermNotesAndLoans>
    <us-gaap:Liabilities
      contextRef="AsOf2026-09-30"
      decimals="0"
      id="Fact000090"
      unitRef="USD">11157493</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="AsOf2025-12-31"
      decimals="0"
      id="Fact000091"
      unitRef="USD">10390348</us-gaap:Liabilities>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="AsOf2026-09-30"
      decimals="INF"
      id="Fact000098"
      unitRef="USDPShares">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="AsOf2025-12-31"
      decimals="INF"
      id="Fact000099"
      unitRef="USDPShares">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="AsOf2026-09-30"
      decimals="INF"
      id="Fact000100"
      unitRef="Shares">200000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="AsOf2025-12-31"
      decimals="INF"
      id="Fact000101"
      unitRef="Shares">200000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued
      contextRef="AsOf2026-09-30"
      decimals="INF"
      id="Fact000102"
      unitRef="Shares">5403843</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="AsOf2026-09-30"
      decimals="INF"
      id="Fact000103"
      unitRef="Shares">5403843</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="AsOf2025-12-31"
      decimals="INF"
      id="Fact000104"
      unitRef="Shares">5403843</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="AsOf2025-12-31"
      decimals="INF"
      id="Fact000105"
      unitRef="Shares">5403843</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockValue
      contextRef="AsOf2026-09-30"
      decimals="0"
      id="Fact000096"
      unitRef="USD">5404</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="AsOf2025-12-31"
      decimals="0"
      id="Fact000097"
      unitRef="USD">5404</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapital
      contextRef="AsOf2026-09-30"
      decimals="0"
      id="Fact000107"
      unitRef="USD">30741991</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AdditionalPaidInCapital
      contextRef="AsOf2025-12-31"
      decimals="0"
      id="Fact000108"
      unitRef="USD">30741991</us-gaap:AdditionalPaidInCapital>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="AsOf2026-09-30"
      decimals="0"
      id="Fact000110"
      unitRef="USD">-41788577</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="AsOf2025-12-31"
      decimals="0"
      id="Fact000111"
      unitRef="USD">-41010176</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2026-09-30"
      decimals="0"
      id="Fact000113"
      unitRef="USD">-11041182</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2025-12-31"
      decimals="0"
      id="Fact000114"
      unitRef="USD">-10262781</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="AsOf2026-09-30"
      decimals="0"
      id="Fact000116"
      unitRef="USD">116311</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="AsOf2025-12-31"
      decimals="0"
      id="Fact000117"
      unitRef="USD">127567</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:Revenues
      contextRef="From2026-07-012026-09-30"
      decimals="0"
      id="Fact000119"
      unitRef="USD">6166</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="From2025-07-012025-09-30"
      decimals="0"
      id="Fact000120"
      unitRef="USD">5000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="From2026-01-01to2026-09-30"
      decimals="0"
      id="Fact000121"
      unitRef="USD">16166</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="From2025-01-012025-09-30"
      decimals="0"
      id="Fact000122"
      unitRef="USD">15000</us-gaap:Revenues>
    <us-gaap:GrossProfit
      contextRef="From2026-07-012026-09-30"
      decimals="0"
      id="Fact000129"
      unitRef="USD">6166</us-gaap:GrossProfit>
    <us-gaap:GrossProfit
      contextRef="From2025-07-012025-09-30"
      decimals="0"
      id="Fact000130"
      unitRef="USD">5000</us-gaap:GrossProfit>
    <us-gaap:GrossProfit
      contextRef="From2026-01-01to2026-09-30"
      decimals="0"
      id="Fact000131"
      unitRef="USD">16166</us-gaap:GrossProfit>
    <us-gaap:GrossProfit
      contextRef="From2025-01-012025-09-30"
      decimals="0"
      id="Fact000132"
      unitRef="USD">15000</us-gaap:GrossProfit>
    <us-gaap:DepreciationAndAmortization
      contextRef="From2026-07-012026-09-30"
      decimals="0"
      id="Fact000139"
      unitRef="USD">5184</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization
      contextRef="From2025-07-012025-09-30"
      decimals="0"
      id="Fact000140"
      unitRef="USD">5118</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization
      contextRef="From2026-01-01to2026-09-30"
      decimals="0"
      id="Fact000141"
      unitRef="USD">15187</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization
      contextRef="From2025-01-012025-09-30"
      decimals="0"
      id="Fact000142"
      unitRef="USD">15121</us-gaap:DepreciationAndAmortization>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="From2026-07-012026-09-30"
      decimals="0"
      id="Fact000144"
      unitRef="USD">112378</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="From2025-07-012025-09-30"
      decimals="0"
      id="Fact000145"
      unitRef="USD">105939</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="From2026-01-01to2026-09-30"
      decimals="0"
      id="Fact000146"
      unitRef="USD">351130</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="From2025-01-012025-09-30"
      decimals="0"
      id="Fact000147"
      unitRef="USD">382025</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:OperatingExpenses
      contextRef="From2026-07-012026-09-30"
      decimals="0"
      id="Fact000149"
      unitRef="USD">117562</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="From2025-07-012025-09-30"
      decimals="0"
      id="Fact000150"
      unitRef="USD">111057</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="From2026-01-01to2026-09-30"
      decimals="0"
      id="Fact000151"
      unitRef="USD">366317</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="From2025-01-012025-09-30"
      decimals="0"
      id="Fact000152"
      unitRef="USD">397146</us-gaap:OperatingExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="From2026-07-012026-09-30"
      decimals="0"
      id="Fact000154"
      unitRef="USD">-111396</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="From2025-07-012025-09-30"
      decimals="0"
      id="Fact000155"
      unitRef="USD">-106057</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="From2026-01-01to2026-09-30"
      decimals="0"
      id="Fact000156"
      unitRef="USD">-350151</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="From2025-01-012025-09-30"
      decimals="0"
      id="Fact000157"
      unitRef="USD">-382146</us-gaap:OperatingIncomeLoss>
    <us-gaap:OtherIncome
      contextRef="From2025-01-012025-09-30"
      decimals="0"
      id="Fact000167"
      unitRef="USD">4530</us-gaap:OtherIncome>
    <us-gaap:InterestExpense
      contextRef="From2026-07-012026-09-30"
      decimals="0"
      id="Fact000169"
      unitRef="USD">144288</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="From2025-07-012025-09-30"
      decimals="0"
      id="Fact000170"
      unitRef="USD">144188</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="From2026-01-01to2026-09-30"
      decimals="0"
      id="Fact000171"
      unitRef="USD">428250</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="From2025-01-012025-09-30"
      decimals="0"
      id="Fact000172"
      unitRef="USD">428061</us-gaap:InterestExpense>
    <us-gaap:OtherExpenses
      contextRef="From2026-07-012026-09-30"
      decimals="0"
      id="Fact000174"
      unitRef="USD">144288</us-gaap:OtherExpenses>
    <us-gaap:OtherExpenses
      contextRef="From2025-07-012025-09-30"
      decimals="0"
      id="Fact000175"
      unitRef="USD">144188</us-gaap:OtherExpenses>
    <us-gaap:OtherExpenses
      contextRef="From2026-01-01to2026-09-30"
      decimals="0"
      id="Fact000176"
      unitRef="USD">428250</us-gaap:OtherExpenses>
    <us-gaap:OtherExpenses
      contextRef="From2025-01-012025-09-30"
      decimals="0"
      id="Fact000177"
      unitRef="USD">423531</us-gaap:OtherExpenses>
    <us-gaap:NetIncomeLoss
      contextRef="From2026-07-012026-09-30"
      decimals="0"
      id="Fact000179"
      unitRef="USD">-255684</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2025-07-012025-09-30"
      decimals="0"
      id="Fact000180"
      unitRef="USD">-250245</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2026-01-01to2026-09-30"
      decimals="0"
      id="Fact000181"
      unitRef="USD">-778401</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2025-01-012025-09-30"
      decimals="0"
      id="Fact000182"
      unitRef="USD">-805677</us-gaap:NetIncomeLoss>
    <us-gaap:IncomeLossFromContinuingOperationsPerBasicShare
      contextRef="From2026-07-012026-09-30"
      decimals="INF"
      id="Fact000184"
      unitRef="USDPShares">-0.05</us-gaap:IncomeLossFromContinuingOperationsPerBasicShare>
    <us-gaap:IncomeLossFromContinuingOperationsPerBasicShare
      contextRef="From2025-07-012025-09-30"
      decimals="INF"
      id="Fact000185"
      unitRef="USDPShares">-0.05</us-gaap:IncomeLossFromContinuingOperationsPerBasicShare>
    <us-gaap:IncomeLossFromContinuingOperationsPerBasicShare
      contextRef="From2026-01-01to2026-09-30"
      decimals="INF"
      id="Fact000186"
      unitRef="USDPShares">-0.14</us-gaap:IncomeLossFromContinuingOperationsPerBasicShare>
    <us-gaap:IncomeLossFromContinuingOperationsPerBasicShare
      contextRef="From2025-01-012025-09-30"
      decimals="INF"
      id="Fact000187"
      unitRef="USDPShares">-0.15</us-gaap:IncomeLossFromContinuingOperationsPerBasicShare>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="From2026-07-012026-09-30"
      decimals="INF"
      id="Fact000189"
      unitRef="Shares">5403843</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="From2025-07-012025-09-30"
      decimals="INF"
      id="Fact000190"
      unitRef="Shares">5403843</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="From2026-01-01to2026-09-30"
      decimals="INF"
      id="Fact000191"
      unitRef="Shares">5403843</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="From2025-01-012025-09-30"
      decimals="INF"
      id="Fact000192"
      unitRef="Shares">5390409</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:SharesIssued
      contextRef="AsOf2025-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000199"
      unitRef="Shares">5403843</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2025-12-31_us-gaap_CommonStockMember"
      decimals="0"
      id="Fact000194"
      unitRef="USD">5404</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2025-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000195"
      unitRef="USD">30741991</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2025-12-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="Fact000197"
      unitRef="USD">-41010176</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2025-12-31"
      decimals="0"
      id="Fact000198"
      unitRef="USD">-10262781</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss
      contextRef="From2026-01-012026-03-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="Fact000204"
      unitRef="USD">-267184</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2026-01-012026-03-31"
      decimals="0"
      id="Fact000205"
      unitRef="USD">-267184</us-gaap:NetIncomeLoss>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2026-03-31_us-gaap_CommonStockMember"
      decimals="0"
      id="Fact000208"
      unitRef="USD">5404</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2026-03-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000209"
      unitRef="USD">30741991</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2026-03-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="Fact000211"
      unitRef="USD">-41277360</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2026-03-31"
      decimals="0"
      id="Fact000212"
      unitRef="USD">-10529965</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss
      contextRef="From2026-04-012026-06-30_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="Fact000217"
      unitRef="USD">-255533</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2026-04-012026-06-30"
      decimals="0"
      id="Fact000218"
      unitRef="USD">-255533</us-gaap:NetIncomeLoss>
    <us-gaap:SharesIssued
      contextRef="AsOf2026-06-30_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000226"
      unitRef="Shares">5403843</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2026-06-30_us-gaap_CommonStockMember"
      decimals="0"
      id="Fact000221"
      unitRef="USD">5404</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2026-06-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000222"
      unitRef="USD">30741991</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2026-06-30_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="Fact000224"
      unitRef="USD">-41532893</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2026-06-30"
      decimals="0"
      id="Fact000225"
      unitRef="USD">-10785498</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss
      contextRef="From2026-07-012026-09-30_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="Fact000231"
      unitRef="USD">-255684</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2026-07-012026-09-30"
      decimals="0"
      id="Fact000232"
      unitRef="USD">-255684</us-gaap:NetIncomeLoss>
    <us-gaap:SharesIssued
      contextRef="AsOf2026-09-30_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000240"
      unitRef="Shares">5403843</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2026-09-30_us-gaap_CommonStockMember"
      decimals="0"
      id="Fact000235"
      unitRef="USD">5404</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2026-09-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000236"
      unitRef="USD">30741991</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2026-09-30_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="Fact000238"
      unitRef="USD">-41788577</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2026-09-30"
      decimals="0"
      id="Fact000239"
      unitRef="USD">-11041182</us-gaap:StockholdersEquity>
    <us-gaap:SharesIssued
      contextRef="AsOf2024-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000247"
      unitRef="Shares">5316843</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-12-31_us-gaap_CommonStockMember"
      decimals="0"
      id="Fact000242"
      unitRef="USD">5317</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000243"
      unitRef="USD">30707298</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-12-31_custom_StockPayableMember"
      decimals="0"
      id="Fact000244"
      unitRef="USD">10000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-12-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="Fact000245"
      unitRef="USD">-39946142</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000246"
      unitRef="USD">-9223527</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesOther
      contextRef="From2025-01-012025-03-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000254"
      unitRef="Shares">87000</us-gaap:StockIssuedDuringPeriodSharesOther>
    <us-gaap:StockIssuedDuringPeriodValueOther
      contextRef="From2025-01-012025-03-31_us-gaap_CommonStockMember"
      decimals="0"
      id="Fact000249"
      unitRef="USD">87</us-gaap:StockIssuedDuringPeriodValueOther>
    <us-gaap:StockIssuedDuringPeriodValueOther
      contextRef="From2025-01-012025-03-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000250"
      unitRef="USD">34693</us-gaap:StockIssuedDuringPeriodValueOther>
    <us-gaap:StockIssuedDuringPeriodValueOther
      contextRef="From2025-01-012025-03-31_custom_StockPayableMember"
      decimals="0"
      id="Fact000251"
      unitRef="USD">-10000</us-gaap:StockIssuedDuringPeriodValueOther>
    <us-gaap:StockIssuedDuringPeriodValueOther
      contextRef="From2025-01-012025-03-31"
      decimals="0"
      id="Fact000253"
      unitRef="USD">24780</us-gaap:StockIssuedDuringPeriodValueOther>
    <us-gaap:NetIncomeLoss
      contextRef="From2025-01-012025-03-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="Fact000259"
      unitRef="USD">-281005</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2025-01-012025-03-31"
      decimals="0"
      id="Fact000260"
      unitRef="USD">-281005</us-gaap:NetIncomeLoss>
    <us-gaap:SharesIssued
      contextRef="AsOf2025-03-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000268"
      unitRef="Shares">5403843</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2025-03-31_us-gaap_CommonStockMember"
      decimals="0"
      id="Fact000263"
      unitRef="USD">5404</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2025-03-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000264"
      unitRef="USD">30741991</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2025-03-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="Fact000266"
      unitRef="USD">-40227147</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2025-03-31"
      decimals="0"
      id="Fact000267"
      unitRef="USD">-9479752</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss
      contextRef="From2025-04-012025-06-30_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="Fact000273"
      unitRef="USD">-274427</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2025-04-012025-06-30"
      decimals="0"
      id="Fact000274"
      unitRef="USD">-274427</us-gaap:NetIncomeLoss>
    <us-gaap:SharesIssued
      contextRef="AsOf2025-06-30_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000282"
      unitRef="Shares">5403843</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2025-06-30_us-gaap_CommonStockMember"
      decimals="0"
      id="Fact000277"
      unitRef="USD">5404</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2025-06-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000278"
      unitRef="USD">30741991</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2025-06-30_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="Fact000280"
      unitRef="USD">-40501574</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2025-06-30"
      decimals="0"
      id="Fact000281"
      unitRef="USD">-9754179</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss
      contextRef="From2025-07-012025-09-30_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="Fact000287"
      unitRef="USD">-250245</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2025-07-012025-09-30"
      decimals="0"
      id="Fact000288"
      unitRef="USD">-250245</us-gaap:NetIncomeLoss>
    <us-gaap:SharesIssued
      contextRef="AsOf2025-09-30_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000296"
      unitRef="Shares">5403843</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2025-09-30_us-gaap_CommonStockMember"
      decimals="0"
      id="Fact000291"
      unitRef="USD">5404</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2025-09-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000292"
      unitRef="USD">30741991</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2025-09-30_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="Fact000294"
      unitRef="USD">-40751819</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2025-09-30"
      decimals="0"
      id="Fact000295"
      unitRef="USD">-10004424</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss
      contextRef="From2026-01-01to2026-09-30"
      decimals="0"
      id="Fact000301"
      unitRef="USD">-778401</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2025-01-012025-09-30"
      decimals="0"
      id="Fact000302"
      unitRef="USD">-805677</us-gaap:NetIncomeLoss>
    <us-gaap:DepreciationAndAmortization
      contextRef="From2026-01-01to2026-09-30"
      decimals="0"
      id="Fact000307"
      unitRef="USD">15187</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization
      contextRef="From2025-01-012025-09-30"
      decimals="0"
      id="Fact000308"
      unitRef="USD">15121</us-gaap:DepreciationAndAmortization>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="From2026-01-01to2026-09-30"
      decimals="0"
      id="Fact000313"
      unitRef="USD">-2181</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="From2025-01-012025-09-30"
      decimals="0"
      id="Fact000314"
      unitRef="USD">3868</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
      contextRef="From2026-01-01to2026-09-30"
      decimals="0"
      id="Fact000316"
      unitRef="USD">247997</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
      contextRef="From2025-01-012025-09-30"
      decimals="0"
      id="Fact000317"
      unitRef="USD">297663</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:DebtInstrumentIncreaseAccruedInterest
      contextRef="From2026-01-01to2026-09-30"
      decimals="0"
      id="Fact000319"
      unitRef="USD">428247</us-gaap:DebtInstrumentIncreaseAccruedInterest>
    <us-gaap:DebtInstrumentIncreaseAccruedInterest
      contextRef="From2025-01-012025-09-30"
      decimals="0"
      id="Fact000320"
      unitRef="USD">428060</us-gaap:DebtInstrumentIncreaseAccruedInterest>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="From2026-01-01to2026-09-30"
      decimals="0"
      id="Fact000322"
      unitRef="USD">-89151</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="From2025-01-012025-09-30"
      decimals="0"
      id="Fact000323"
      unitRef="USD">-60965</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquireProductiveAssets
      contextRef="From2025-01-012025-09-30"
      decimals="0"
      id="Fact000329"
      unitRef="USD">4086</us-gaap:PaymentsToAcquireProductiveAssets>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="From2025-01-012025-09-30"
      decimals="0"
      id="Fact000332"
      unitRef="USD">-4086</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="From2025-01-012025-09-30"
      decimals="0"
      id="Fact000338"
      unitRef="USD">24780</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromNotesPayable
      contextRef="From2025-01-012025-09-30"
      decimals="0"
      id="Fact000341"
      unitRef="USD">10000</us-gaap:ProceedsFromNotesPayable>
    <us-gaap:PaymentsToFundLongtermLoansToRelatedParties
      contextRef="From2026-01-01to2026-09-30"
      decimals="0"
      id="Fact000343"
      unitRef="USD">90901</us-gaap:PaymentsToFundLongtermLoansToRelatedParties>
    <us-gaap:PaymentsToFundLongtermLoansToRelatedParties
      contextRef="From2025-01-012025-09-30"
      decimals="0"
      id="Fact000344"
      unitRef="USD">20580</us-gaap:PaymentsToFundLongtermLoansToRelatedParties>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="From2026-01-01to2026-09-30"
      decimals="0"
      id="Fact000346"
      unitRef="USD">90901</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="From2025-01-012025-09-30"
      decimals="0"
      id="Fact000347"
      unitRef="USD">55360</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="From2026-01-01to2026-09-30"
      decimals="0"
      id="Fact000349"
      unitRef="USD">1750</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="From2025-01-012025-09-30"
      decimals="0"
      id="Fact000350"
      unitRef="USD">-9691</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="AsOf2025-12-31"
      decimals="0"
      id="Fact000352"
      unitRef="USD">2620</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000353"
      unitRef="USD">10336</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="AsOf2026-09-30"
      decimals="0"
      id="Fact000355"
      unitRef="USD">4370</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="AsOf2025-09-30"
      decimals="0"
      id="Fact000356"
      unitRef="USD">645</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock contextRef="From2026-01-01to2026-09-30" id="Fact000367">&lt;p id="xdx_80C_eus-gaap--BusinessDescriptionAndBasisOfPresentationTextBlock_zorpL72IedJl" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;1.&#160;&#160;&#160;&#160;&#160;&#160;&#160;DESCRIPTION OF BUSINESS
AND HISTORY&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_842_eus-gaap--BusinessDescriptionAndAccountingPoliciesTextBlock_zZyxAttzR6v8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="text-decoration: underline"&gt;Description of business&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Skinvisible, Inc., (referred to as the &#x201c;Company&#x201d;)
is focused on the development, manufacture and sales of innovative topical, transdermal and mucosal polymer-based delivery system technologies
and formulations incorporating its patent-pending formula/process for combining hydrophilic and hydrophobic polymer emulsions. The technologies
and formulations have broad industry applications within the pharmaceutical, over-the-counter, personal skincare and cosmetic arenas.
Additionally, the Company&#x2019;s non-dermatological formulations offer solutions for a broad spectrum of markets including women&#x2019;s
health, pain management, and others. The Company maintains executive and sales offices in Las Vegas, Nevada.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_844_ecustom--HistoryPolicyTextBlock_z1AjFdKoaCaf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="text-decoration: underline"&gt;History&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Company was incorporated in &lt;span id="xdx_903_edei--EntityIncorporationStateCountryCode_c20260101__20260930_ztGQzbAkZnT4"&gt;Nevada&lt;/span&gt; on &lt;span id="xdx_90C_edei--EntityIncorporationDateOfIncorporation_c20260101__20260930_zTjtdXiA5Xc6"&gt;March
6, 1998&lt;/span&gt;, under the name of Microbial Solutions, Inc. The Company underwent a name change on February 26, 1999, when it changed its name
to Skinvisible, Inc. The Company&#x2019;s subsidiary&#x2019;s name of Manloe Labs, Inc. was also changed to Skinvisible Pharmaceuticals,
Inc.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Skinvisible, Inc., together with its subsidiaries,
shall herein be collectively referred to as the &#x201c;Company.&#x201d;&lt;/p&gt;

&lt;p id="xdx_855_zaShwkjh9rrk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&#160;&lt;/p&gt;

</us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock>
    <us-gaap:BusinessDescriptionAndAccountingPoliciesTextBlock contextRef="From2026-01-01to2026-09-30" id="Fact000369">&lt;p id="xdx_842_eus-gaap--BusinessDescriptionAndAccountingPoliciesTextBlock_zZyxAttzR6v8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="text-decoration: underline"&gt;Description of business&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Skinvisible, Inc., (referred to as the &#x201c;Company&#x201d;)
is focused on the development, manufacture and sales of innovative topical, transdermal and mucosal polymer-based delivery system technologies
and formulations incorporating its patent-pending formula/process for combining hydrophilic and hydrophobic polymer emulsions. The technologies
and formulations have broad industry applications within the pharmaceutical, over-the-counter, personal skincare and cosmetic arenas.
Additionally, the Company&#x2019;s non-dermatological formulations offer solutions for a broad spectrum of markets including women&#x2019;s
health, pain management, and others. The Company maintains executive and sales offices in Las Vegas, Nevada.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

</us-gaap:BusinessDescriptionAndAccountingPoliciesTextBlock>
    <SKVI:HistoryPolicyTextBlock contextRef="From2026-01-01to2026-09-30" id="Fact000371">&lt;p id="xdx_844_ecustom--HistoryPolicyTextBlock_z1AjFdKoaCaf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="text-decoration: underline"&gt;History&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Company was incorporated in &lt;span id="xdx_903_edei--EntityIncorporationStateCountryCode_c20260101__20260930_ztGQzbAkZnT4"&gt;Nevada&lt;/span&gt; on &lt;span id="xdx_90C_edei--EntityIncorporationDateOfIncorporation_c20260101__20260930_zTjtdXiA5Xc6"&gt;March
6, 1998&lt;/span&gt;, under the name of Microbial Solutions, Inc. The Company underwent a name change on February 26, 1999, when it changed its name
to Skinvisible, Inc. The Company&#x2019;s subsidiary&#x2019;s name of Manloe Labs, Inc. was also changed to Skinvisible Pharmaceuticals,
Inc.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Skinvisible, Inc., together with its subsidiaries,
shall herein be collectively referred to as the &#x201c;Company.&#x201d;&lt;/p&gt;

</SKVI:HistoryPolicyTextBlock>
    <dei:EntityIncorporationStateCountryCode contextRef="From2026-01-01to2026-09-30" id="Fact000372">NV</dei:EntityIncorporationStateCountryCode>
    <dei:EntityIncorporationDateOfIncorporation contextRef="From2026-01-01to2026-09-30" id="Fact000373">1998-03-06</dei:EntityIncorporationDateOfIncorporation>
    <us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock contextRef="From2026-01-01to2026-09-30" id="Fact000375">&lt;p id="xdx_806_eus-gaap--BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_zan1AQ62HG0i" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;2.&#160;&#160;&#160;&#160;&#160;&#160;&#160;BASIS
OF PRESENTATION AND GOING CONCERN&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_842_eus-gaap--BasisOfAccounting_zDjP2nt1ThMl" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="text-decoration: underline"&gt;Basis of presentation&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The accompanying unaudited condensed consolidated
financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America for
interim financial information and the instructions to Form 10-Q and Article 8 of Regulation S-X. Accordingly, they do not include all
of the information and disclosures required for complete annual financial statements and should be read together with the Company&#x2019;s
consolidated financial statements and related notes for the year ended December 31, 2025. In the opinion of management, all adjustments,
consisting of normal recurring adjustments, necessary for a fair presentation have been included. Results for the three and nine months
ended September 30, 2026 are not necessarily indicative of results for the full year.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_849_eus-gaap--SubstantialDoubtAboutGoingConcernTextBlock_zL2jdyPUzeif" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="text-decoration: underline"&gt;Going concern&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;The accompanying financial statements have been
prepared on a going concern basis, which contemplates the realization of assets and the satisfaction of liabilities in the normal course
of business. For the nine months ended September 30, 2026, the Company had a net loss of &lt;span id="xdx_90B_eus-gaap--NetIncomeLoss_iN_pp0p0_di_c20260101__20260930_zLjjaWM2r1ca"&gt;$778,401&lt;/span&gt;. The Company has also incurred cumulative
net losses of &lt;span id="xdx_90D_eus-gaap--NetIncomeLoss_iN_pp0p0_di_c20011206__20260930_zSl2NsAGY9t4"&gt;$41,788,577&lt;/span&gt; since its inception and requires capital for its contemplated operational and marketing activities to take place.
These factors, among others, raise substantial doubt about the Company&#x2019;s ability to continue as a going concern within one year
after the date that the financial statements are issued. Management&#x2019;s plans for the Company are to generate the necessary funding
through licensing of its core products and to seek additional debt and equity funding. However, the Company&#x2019;s ability to generate
the necessary funds through licensing or raise additional capital through the future issuances of common stock or debt is unknown. The
obtainment of additional financing, the successful development of the Company&#x2019;s contemplated plan of operations, and its transition,
ultimately, to the attainment of profitable operations are necessary for the Company to continue operations. The consolidated financial
statements of the Company do not include any adjustments that may result from the outcome of these aforementioned uncertainties.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;/p&gt;

&lt;p id="xdx_842_eus-gaap--Reclassifications_zT9A968Cchr7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="text-decoration: underline"&gt;Reclassification&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="text-decoration: underline"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="text-decoration: underline"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;During the period ended September 30, 2026,
the Company identified an error in the historical classification of cash flows related to changes in its "Due to Related Party"
balances. Previously, net changes in "Due to Related Party" were incorrectly classified as cash flows from operating activities
rather than cash flows from financing activities pursuant to FASB ASC 230.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;To conform to the proper accounting standard,
the Company has reclassified these amounts in the accompanying statement of cash flows for the comparative prior periods. Management evaluated
this misclassification and determined that it is immaterial to the previously issued interim and annual financial statements.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;This correction had no impact on the Company&#x2019;s
total assets, total liabilities, net loss, or the net change in cash and cash equivalents for any previously reported period.&lt;/p&gt;

&lt;p id="xdx_855_z22S0Ng8MGR5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0.35pt 0 6pt; text-align: justify"&gt;&lt;/p&gt;

</us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock>
    <us-gaap:BasisOfAccounting contextRef="From2026-01-01to2026-09-30" id="Fact000377">&lt;p id="xdx_842_eus-gaap--BasisOfAccounting_zDjP2nt1ThMl" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="text-decoration: underline"&gt;Basis of presentation&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The accompanying unaudited condensed consolidated
financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America for
interim financial information and the instructions to Form 10-Q and Article 8 of Regulation S-X. Accordingly, they do not include all
of the information and disclosures required for complete annual financial statements and should be read together with the Company&#x2019;s
consolidated financial statements and related notes for the year ended December 31, 2025. In the opinion of management, all adjustments,
consisting of normal recurring adjustments, necessary for a fair presentation have been included. Results for the three and nine months
ended September 30, 2026 are not necessarily indicative of results for the full year.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

</us-gaap:BasisOfAccounting>
    <us-gaap:SubstantialDoubtAboutGoingConcernTextBlock contextRef="From2026-01-01to2026-09-30" id="Fact000379">&lt;p id="xdx_849_eus-gaap--SubstantialDoubtAboutGoingConcernTextBlock_zL2jdyPUzeif" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="text-decoration: underline"&gt;Going concern&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;The accompanying financial statements have been
prepared on a going concern basis, which contemplates the realization of assets and the satisfaction of liabilities in the normal course
of business. For the nine months ended September 30, 2026, the Company had a net loss of &lt;span id="xdx_90B_eus-gaap--NetIncomeLoss_iN_pp0p0_di_c20260101__20260930_zLjjaWM2r1ca"&gt;$778,401&lt;/span&gt;. The Company has also incurred cumulative
net losses of &lt;span id="xdx_90D_eus-gaap--NetIncomeLoss_iN_pp0p0_di_c20011206__20260930_zSl2NsAGY9t4"&gt;$41,788,577&lt;/span&gt; since its inception and requires capital for its contemplated operational and marketing activities to take place.
These factors, among others, raise substantial doubt about the Company&#x2019;s ability to continue as a going concern within one year
after the date that the financial statements are issued. Management&#x2019;s plans for the Company are to generate the necessary funding
through licensing of its core products and to seek additional debt and equity funding. However, the Company&#x2019;s ability to generate
the necessary funds through licensing or raise additional capital through the future issuances of common stock or debt is unknown. The
obtainment of additional financing, the successful development of the Company&#x2019;s contemplated plan of operations, and its transition,
ultimately, to the attainment of profitable operations are necessary for the Company to continue operations. The consolidated financial
statements of the Company do not include any adjustments that may result from the outcome of these aforementioned uncertainties.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;/p&gt;

</us-gaap:SubstantialDoubtAboutGoingConcernTextBlock>
    <us-gaap:NetIncomeLoss
      contextRef="From2026-01-01to2026-09-30"
      decimals="0"
      id="Fact000380"
      unitRef="USD">-778401</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2001-12-062026-09-30"
      decimals="0"
      id="Fact000381"
      unitRef="USD">-41788577</us-gaap:NetIncomeLoss>
    <us-gaap:Reclassifications contextRef="From2026-01-01to2026-09-30" id="Fact000383">&lt;p id="xdx_842_eus-gaap--Reclassifications_zT9A968Cchr7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="text-decoration: underline"&gt;Reclassification&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="text-decoration: underline"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="text-decoration: underline"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;During the period ended September 30, 2026,
the Company identified an error in the historical classification of cash flows related to changes in its "Due to Related Party"
balances. Previously, net changes in "Due to Related Party" were incorrectly classified as cash flows from operating activities
rather than cash flows from financing activities pursuant to FASB ASC 230.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;To conform to the proper accounting standard,
the Company has reclassified these amounts in the accompanying statement of cash flows for the comparative prior periods. Management evaluated
this misclassification and determined that it is immaterial to the previously issued interim and annual financial statements.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;This correction had no impact on the Company&#x2019;s
total assets, total liabilities, net loss, or the net change in cash and cash equivalents for any previously reported period.&lt;/p&gt;

</us-gaap:Reclassifications>
    <us-gaap:SignificantAccountingPoliciesTextBlock contextRef="From2026-01-01to2026-09-30" id="Fact000385">&lt;p id="xdx_80E_eus-gaap--SignificantAccountingPoliciesTextBlock_zWnsetO3Ycbg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;3.&#160;&#160;&#160;&#160;&#160;&#160;&#160;SUMMARY OF SIGNIFICANT
POLICIES&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;This summary of significant accounting
policies of Skinvisible Inc. is presented to assist in understanding the Company&#x2019;s consolidated financial statements. The consolidated
financial statements and notes are representations of the Company&#x2019;s management, &lt;span style="letter-spacing: -0.15pt"&gt;who &lt;/span&gt;are
responsible for their integrity and objectivity. These accounting policies conform to accounting principles generally accepted in the
United States of America and have been consistently applied in the preparation of the consolidated financial statements.&#160;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_845_eus-gaap--ConsolidationPolicyTextBlock_z1vdkFNjpt6i" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="text-decoration: underline"&gt;Principles of consolidation&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;The consolidated financial statements include
the accounts of the Company and its subsidiary Skinvisible Pharmaceuticals Inc. All significant intercompany balances and transactions
have been eliminated.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_84A_eus-gaap--UseOfEstimates_zjbNdOpEPAmg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="text-decoration: underline"&gt;Use of estimates&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;The preparation of consolidated financial statements
in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and
assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities at the date of
the consolidated financial statements, and the reported amounts of revenues and expenses during the reporting period. Actual results could
differ from those estimates. Significant estimates include estimates used to review the Company&#x2019;s impairments and estimations of
long-lived assets, allowances for uncollectible accounts, inventory valuation, and the valuations of non-cash capital stock issuances.
The Company bases its estimates on historical experience and on various other assumptions that are believed to be reasonable in the circumstances,
the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent
from other sources. Actual results may differ from these estimates under different assumptions or conditions.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_849_eus-gaap--CashAndCashEquivalentsPolicyTextBlock_ztdbg7C2weVc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="text-decoration: underline"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;For purposes of the statement of cash flows,
the Company considers all highly liquid investments and short-term instruments with original maturities of three months or less to be
cash equivalents.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_84E_eus-gaap--FairValueOfFinancialInstrumentsPolicy_zwtxtNS0JyWg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="text-decoration: underline"&gt;Fair Value of financial instruments&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;The carrying value of cash, accounts payable
and accrued expenses, and debt (See Notes 5, 6 and 7) approximate their fair values because of the short-term nature of these instruments.
Management believes the Company is not exposed to significant interest or credit risks arising from these financial instruments. The carrying
amount of the Company&#x2019;s convertible debt is also stated at a fair value of &lt;span id="xdx_902_eus-gaap--DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent_iI_c20260930_z6eAwAkiAMsc"&gt;$5,724,478&lt;/span&gt; since the stated rate of interest approximates
market rates.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;Fair value is defined as the exchange price
that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the
asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure
fair value maximize the use of observable inputs and minimize the use of unobservable inputs. The Company utilizes a fair value hierarchy
based on three levels of inputs, of which the first two are considered observable and the last unobservable.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 12pt Arial, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 16px"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 13px; text-align: justify; line-height: 90%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; letter-spacing: -1.05pt; line-height: 90%"&gt;&#x2022;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;p style="margin-top: 0; margin-bottom: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Level 1 Quoted prices in active markets for identical assets or liabilities. These are typically obtained from real-time quotes for transactions in active exchange markets involving identical assets. The Company uses Level 1 measurements to value the transactions when it issues shares, warrants, options and debt with beneficial conversion features.&lt;/span&gt;&lt;/p&gt;
                                    &lt;p style="margin-top: 0; margin-bottom: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: justify; line-height: 90%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; letter-spacing: -1.05pt; line-height: 90%"&gt;&#x2022;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;p style="margin-top: 0; margin-bottom: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Level 2 Quoted prices for similar assets and liabilities in active markets; quoted prices included for identical or similar assets and liabilities that are not active; and model-derived valuations in which all significant inputs and significant value drivers are observable in active markets. These are typically obtained from readily available pricing sources for comparable instruments. The Company did not rely on any Level 2 measurements for any of its transactions in the periods included in these financial statements.&lt;/span&gt;&lt;/p&gt;
                                    &lt;p style="margin-top: 0; margin-bottom: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: justify; line-height: 90%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; letter-spacing: -1.05pt; line-height: 90%"&gt;&#x2022;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Level 3 Unobservable inputs, where there is little or no market activity for the asset or liability. These inputs reflect the reporting entity&#x2019;s own beliefs about the assumptions that market participants would use in pricing the asset or liability, based on the best information available in the circumstances. The Company did not rely on any Level 3 measurements for any of its transactions in the periods included in these financial statements.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&#160;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 6pt; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;/p&gt;

&lt;p id="xdx_841_eus-gaap--RevenueRecognitionPolicyTextBlock_ziUye5OhrZK3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="text-decoration: underline"&gt;Revenue recognition&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;The Company recognizes revenue in accordance
with generally accepted accounting principles as outlined in the Financial Accounting Standard Board's (&#x201c;FASB&#x201d;) Accounting
Standards Codification (&#x201c;ASC&#x201d;) 606, Revenue From Contracts with Customers, which requires that five steps be followed in evaluating
revenue recognition: (i) identify the contract with the customer; (ii) identify the performance obligations in the contract; (iii) determine
the transaction price; (iv) allocate the transaction price; and (v) recognize revenue when or as the entity satisfied a performance obligation.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in"&gt;&lt;i&gt;Product sales&lt;/i&gt;&#160;&#x2013; Revenues from the sale of
products (Invisicare&#xae; polymers) are recognized when title to the products are transferred to the customer and only when no further
contingencies or material performance obligations are warranted, and thereby have earned the right to receive reasonably assured payments
for products sold and delivered.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in"&gt;&lt;i&gt;Royalty sales&lt;/i&gt;&#160;&#x2013; We also recognize royalty
revenue from licensing our patented product formulations only when earned, with no further contingencies or material performance obligations
are warranted, and thereby have earned the right to receive and retain reasonably assured payments.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in"&gt;&lt;i&gt;Distribution and license rights sales&lt;/i&gt;&#160;&#x2013; We
also recognize revenue from distribution and license rights when no further contingencies or material performance obligations are warranted,
and thereby have earned the right to receive and retain reasonably assured payments.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;The Company has made an accounting policy election
to exclude from the measurement of the transaction price all taxes assessed by governmental authorities that are collected by the Company
from its customers (sales and use taxes, value added taxes, some excise taxes).&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;For the three and nine months ended September
30, 2026, revenue consisted of royalties of &lt;span id="xdx_907_eus-gaap--ProceedsFromRoyaltiesReceived_c20260701__20260930_zwbcRRh0ZZ6c"&gt;$5,000&lt;/span&gt; and &lt;span id="xdx_905_eus-gaap--ProceedsFromRoyaltiesReceived_c20260101__20260930_z5u2Y961A5Ma"&gt;$15,000&lt;/span&gt;, respectively, and product sales of &lt;span id="xdx_902_eus-gaap--SalesCommissionsAndFees_c20260701__20260930_zcvKvjcBpP6b"&gt;&lt;span id="xdx_906_eus-gaap--SalesCommissionsAndFees_c20260101__20260930_z6NFvN4XqZK6"&gt;$1,166&lt;/span&gt;&lt;/span&gt; in each period. For the three
and nine months ended September 30, 2025, revenue was &lt;span id="xdx_90F_eus-gaap--Revenues_c20250701__20250930_zWAXeyUBJ0nc"&gt;$5,000&lt;/span&gt; and &lt;span id="xdx_90F_eus-gaap--Revenues_c20250101__20250930_zmhcWvDtPgD8"&gt;$15,000&lt;/span&gt;, respectively.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_848_eus-gaap--ReceivablesPolicyTextBlock_zDVFwpxL9Vm2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="text-decoration: underline"&gt;Accounts Receivable&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;Accounts receivable is comprised of uncollateralized
customer obligations due under normal trade terms requiring payment within 30 days from the invoice date. The carrying amount of accounts
receivable is reviewed periodically for collectability. If management determines that collection is unlikely, an allowance that reflects
management&#x2019;s best estimate of the amounts that will not be collected is recorded. Management reviews each accounts receivable balance
that exceeds 30 days from the invoice date and, based on an assessment of creditworthiness, estimates the portion, if any, of the balance
that will not be collected. As of September 30, 2026 and December 31, 2025, the Company had determined it was not necessary to recognize
a reserve for doubtful accounts.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_842_eus-gaap--IntangibleAssetsFiniteLivedPolicy_zVZ1v6RccS04" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="text-decoration: underline"&gt;Intangible assets&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;The Company follows Financial Accounting Standard
Board&#x2019;s (FASB) Codification Topic 350-10 (&#x201c;ASC 350-10&#x201d;), &#x201c;&lt;i&gt;Intangibles &#x2013; Goodwill and Other&lt;/i&gt;&#x201d;.
According to this statement, intangible assets with indefinite lives are no longer subject to amortization, but rather an annual assessment
of impairment by applying a fair-value based test.&#160; Under ASC 350-10, the carrying value of assets are calculated at the lowest level
for which there are identifiable cash flows.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_84A_eus-gaap--ScheduleOfShareBasedCompensationEmployeeStockPurchasePlanActivityTableTextBlock_zpaLRa570w4h" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="text-decoration: underline"&gt;Stock-based compensation&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;The Company follows the guidelines in FASB Codification
Topic ASC 718-10 &#x201c;&lt;i&gt;Compensation-Stock Compensation&lt;/i&gt;&#x201d;, which requires the measurement and recognition of compensation
expense for all share-based payment awards made to employees and directors including employee stock options and employee stock purchases
related to an Employee Stock Purchase Plan based on the estimated fair values.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_84D_eus-gaap--EarningsPerSharePolicyTextBlock_z1mR7zq5d2q1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="text-decoration: underline"&gt;Earnings (loss) per share&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;Basic loss per share is computed by dividing
net loss available to common stockholders by the weighted-average number of common shares outstanding during the period. Diluted loss
per share includes potentially dilutive common shares only when their inclusion would be dilutive. For the three and nine months ended
September 30, 2026 and 2025, potentially issuable common shares have been excluded because their effect would be anti-dilutive. Accordingly,
basic and diluted loss per share are the same.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;There are&#160;&lt;span id="xdx_905_eus-gaap--IncrementalCommonSharesAttributableToContingentlyIssuableShares_c20260101__20260930_z25OHXNmeLI7"&gt;82,981,326&lt;/span&gt;&#160;additional
shares issuable in connection with outstanding options, warrants, stock payable and convertible debts as of September 30, 2026 The shares
issuable under each instrument is as follows;&#160;&lt;span id="xdx_907_eus-gaap--WeightedAverageNumberOfSharesContingentlyIssuable_c20260101__20260930__us-gaap--StatementEquityComponentsAxis__custom--ConvertibleNotesMember_ze8c2He98Of2"&gt;82,981,326&lt;/span&gt;&#160;shares issuable under convertible notes.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0.45pt 0 6pt; text-align: justify"&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0.45pt 0 6pt; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_840_eus-gaap--SegmentReportingPolicyPolicyTextBlock_zFEBKp4l2wH4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="text-decoration: underline"&gt;Segment Reporting&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;The Company determined its reporting units
in accordance with ASC 280,&#160;Segment Reporting. Reportable operating segments are determined based on the management approach, as
defined by ASC 280, which is based on the way that the chief operating decision-maker (&#x201c;CODM&#x201d;) organizes segments within the
Company for making operating decisions, assessing performance, and allocating resources. Reportable segments are based on products and
services, geography, legal structure, management structure, or any other manner in which management disaggregates the Company. The Company
operates as a&#160;single&#160;operating and reportable segment.&#160;The Company has identified its&#160;Chief Executive Officer&#160;as
the CODM, who reviews the Company&#x2019;s financial information for purposes of making operating decisions and assessing financial performance.
The net loss is the measure of segment profit (loss) most consistent with U.S. GAAP that is regularly reviewed by the CODM to allocate
resources and assess financial performance.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_84C_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_zSx3VA9U28Jj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="text-decoration: underline"&gt;Recently issued accounting pronouncements&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;In July 2025, the FASB issued Accounting Standards
Update 2025-05, Financial Instruments &#x2013; Credit Losses (Topic 326): Measurement of Credit Losses for Accounts Receivable and Contract
Assets ("ASU 2025-05"). ASU 2025-05 provides a practical expedient that all entities can use when estimating expected credit
losses for current accounts receivable and current contract assets arising from transactions accounted for under ASC 606, Revenue from
Contracts with Customers. Under this practical expedient, an entity is allowed to assume that the current conditions it has applied in
determining credit loss allowances for current accounts receivable and current contract assets remain unchanged for the remaining life
of those assets. ASU 2025-05 is effective for fiscal years beginning after December 15, 2025, and interim reporting periods in those years.
Entities that elect the practical expedient and, if applicable, make the accounting policy election are required to apply the amendments
prospectively. The Company has evaluated the impact of ASU 2025-05 on its financial statements and disclosures and has determined that
it does not have a material impact on the financial statements.&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;In November 2025, the FASB issued ASU No. 2025-11,
Interim Reporting (Topic 270): Narrow-Scope Improvements. The amendments clarify and reorganize existing interim reporting guidance, including
the scope of Topic 270 and interim disclosure requirements, and introduce a disclosure principle requiring entities to disclose material
events or changes occurring since the most recent annual reporting period. ASU 2025-11 is effective for interim reporting periods within
annual reporting periods beginning after December 15, 2027. Early adoption is permitted. The Company is currently evaluating the impact
of ASU 2025-11 on its financial statements and related disclosures.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;In December 2025, the FASB issued ASU 2025-12,
Accounting Standards Codification Improvements, which clarifies guidance and makes minor improvements across various topics, including
earnings per share, receivables, revenue, income taxes, and equity. This ASU is effective for annual periods beginning after December
15, 2026, and interim periods within those annual periods, with early adoption permitted. The Company is currently evaluating the impact
of the new guidance on its financial statements and disclosures.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;The Company does not believe that other standards,
which have been issued but are not yet effective, will have a significant impact on its financial statements.&lt;/p&gt;

&lt;p id="xdx_85E_z8xLAJnHKL8i" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&#160;&lt;/p&gt;

</us-gaap:SignificantAccountingPoliciesTextBlock>
    <us-gaap:ConsolidationPolicyTextBlock contextRef="From2026-01-01to2026-09-30" id="Fact000387">&lt;p id="xdx_845_eus-gaap--ConsolidationPolicyTextBlock_z1vdkFNjpt6i" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="text-decoration: underline"&gt;Principles of consolidation&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;The consolidated financial statements include
the accounts of the Company and its subsidiary Skinvisible Pharmaceuticals Inc. All significant intercompany balances and transactions
have been eliminated.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&#160;&lt;/p&gt;

</us-gaap:ConsolidationPolicyTextBlock>
    <us-gaap:UseOfEstimates contextRef="From2026-01-01to2026-09-30" id="Fact000389">&lt;p id="xdx_84A_eus-gaap--UseOfEstimates_zjbNdOpEPAmg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="text-decoration: underline"&gt;Use of estimates&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;The preparation of consolidated financial statements
in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and
assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities at the date of
the consolidated financial statements, and the reported amounts of revenues and expenses during the reporting period. Actual results could
differ from those estimates. Significant estimates include estimates used to review the Company&#x2019;s impairments and estimations of
long-lived assets, allowances for uncollectible accounts, inventory valuation, and the valuations of non-cash capital stock issuances.
The Company bases its estimates on historical experience and on various other assumptions that are believed to be reasonable in the circumstances,
the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent
from other sources. Actual results may differ from these estimates under different assumptions or conditions.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&#160;&lt;/p&gt;

</us-gaap:UseOfEstimates>
    <us-gaap:CashAndCashEquivalentsPolicyTextBlock contextRef="From2026-01-01to2026-09-30" id="Fact000391">&lt;p id="xdx_849_eus-gaap--CashAndCashEquivalentsPolicyTextBlock_ztdbg7C2weVc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="text-decoration: underline"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;For purposes of the statement of cash flows,
the Company considers all highly liquid investments and short-term instruments with original maturities of three months or less to be
cash equivalents.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&#160;&lt;/p&gt;

</us-gaap:CashAndCashEquivalentsPolicyTextBlock>
    <us-gaap:FairValueOfFinancialInstrumentsPolicy contextRef="From2026-01-01to2026-09-30" id="Fact000393">&lt;p id="xdx_84E_eus-gaap--FairValueOfFinancialInstrumentsPolicy_zwtxtNS0JyWg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="text-decoration: underline"&gt;Fair Value of financial instruments&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;The carrying value of cash, accounts payable
and accrued expenses, and debt (See Notes 5, 6 and 7) approximate their fair values because of the short-term nature of these instruments.
Management believes the Company is not exposed to significant interest or credit risks arising from these financial instruments. The carrying
amount of the Company&#x2019;s convertible debt is also stated at a fair value of &lt;span id="xdx_902_eus-gaap--DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent_iI_c20260930_z6eAwAkiAMsc"&gt;$5,724,478&lt;/span&gt; since the stated rate of interest approximates
market rates.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;Fair value is defined as the exchange price
that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the
asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure
fair value maximize the use of observable inputs and minimize the use of unobservable inputs. The Company utilizes a fair value hierarchy
based on three levels of inputs, of which the first two are considered observable and the last unobservable.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 12pt Arial, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 16px"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 13px; text-align: justify; line-height: 90%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; letter-spacing: -1.05pt; line-height: 90%"&gt;&#x2022;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;p style="margin-top: 0; margin-bottom: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Level 1 Quoted prices in active markets for identical assets or liabilities. These are typically obtained from real-time quotes for transactions in active exchange markets involving identical assets. The Company uses Level 1 measurements to value the transactions when it issues shares, warrants, options and debt with beneficial conversion features.&lt;/span&gt;&lt;/p&gt;
                                    &lt;p style="margin-top: 0; margin-bottom: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: justify; line-height: 90%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; letter-spacing: -1.05pt; line-height: 90%"&gt;&#x2022;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;p style="margin-top: 0; margin-bottom: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Level 2 Quoted prices for similar assets and liabilities in active markets; quoted prices included for identical or similar assets and liabilities that are not active; and model-derived valuations in which all significant inputs and significant value drivers are observable in active markets. These are typically obtained from readily available pricing sources for comparable instruments. The Company did not rely on any Level 2 measurements for any of its transactions in the periods included in these financial statements.&lt;/span&gt;&lt;/p&gt;
                                    &lt;p style="margin-top: 0; margin-bottom: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: justify; line-height: 90%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; letter-spacing: -1.05pt; line-height: 90%"&gt;&#x2022;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Level 3 Unobservable inputs, where there is little or no market activity for the asset or liability. These inputs reflect the reporting entity&#x2019;s own beliefs about the assumptions that market participants would use in pricing the asset or liability, based on the best information available in the circumstances. The Company did not rely on any Level 3 measurements for any of its transactions in the periods included in these financial statements.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&#160;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 6pt; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;/p&gt;

</us-gaap:FairValueOfFinancialInstrumentsPolicy>
    <us-gaap:DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent
      contextRef="AsOf2026-09-30"
      decimals="0"
      id="Fact000394"
      unitRef="USD">5724478</us-gaap:DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent>
    <us-gaap:RevenueRecognitionPolicyTextBlock contextRef="From2026-01-01to2026-09-30" id="Fact000396">&lt;p id="xdx_841_eus-gaap--RevenueRecognitionPolicyTextBlock_ziUye5OhrZK3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="text-decoration: underline"&gt;Revenue recognition&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;The Company recognizes revenue in accordance
with generally accepted accounting principles as outlined in the Financial Accounting Standard Board's (&#x201c;FASB&#x201d;) Accounting
Standards Codification (&#x201c;ASC&#x201d;) 606, Revenue From Contracts with Customers, which requires that five steps be followed in evaluating
revenue recognition: (i) identify the contract with the customer; (ii) identify the performance obligations in the contract; (iii) determine
the transaction price; (iv) allocate the transaction price; and (v) recognize revenue when or as the entity satisfied a performance obligation.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in"&gt;&lt;i&gt;Product sales&lt;/i&gt;&#160;&#x2013; Revenues from the sale of
products (Invisicare&#xae; polymers) are recognized when title to the products are transferred to the customer and only when no further
contingencies or material performance obligations are warranted, and thereby have earned the right to receive reasonably assured payments
for products sold and delivered.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in"&gt;&lt;i&gt;Royalty sales&lt;/i&gt;&#160;&#x2013; We also recognize royalty
revenue from licensing our patented product formulations only when earned, with no further contingencies or material performance obligations
are warranted, and thereby have earned the right to receive and retain reasonably assured payments.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in"&gt;&lt;i&gt;Distribution and license rights sales&lt;/i&gt;&#160;&#x2013; We
also recognize revenue from distribution and license rights when no further contingencies or material performance obligations are warranted,
and thereby have earned the right to receive and retain reasonably assured payments.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;The Company has made an accounting policy election
to exclude from the measurement of the transaction price all taxes assessed by governmental authorities that are collected by the Company
from its customers (sales and use taxes, value added taxes, some excise taxes).&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;For the three and nine months ended September
30, 2026, revenue consisted of royalties of &lt;span id="xdx_907_eus-gaap--ProceedsFromRoyaltiesReceived_c20260701__20260930_zwbcRRh0ZZ6c"&gt;$5,000&lt;/span&gt; and &lt;span id="xdx_905_eus-gaap--ProceedsFromRoyaltiesReceived_c20260101__20260930_z5u2Y961A5Ma"&gt;$15,000&lt;/span&gt;, respectively, and product sales of &lt;span id="xdx_902_eus-gaap--SalesCommissionsAndFees_c20260701__20260930_zcvKvjcBpP6b"&gt;&lt;span id="xdx_906_eus-gaap--SalesCommissionsAndFees_c20260101__20260930_z6NFvN4XqZK6"&gt;$1,166&lt;/span&gt;&lt;/span&gt; in each period. For the three
and nine months ended September 30, 2025, revenue was &lt;span id="xdx_90F_eus-gaap--Revenues_c20250701__20250930_zWAXeyUBJ0nc"&gt;$5,000&lt;/span&gt; and &lt;span id="xdx_90F_eus-gaap--Revenues_c20250101__20250930_zmhcWvDtPgD8"&gt;$15,000&lt;/span&gt;, respectively.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

</us-gaap:RevenueRecognitionPolicyTextBlock>
    <us-gaap:ProceedsFromRoyaltiesReceived
      contextRef="From2026-07-012026-09-30"
      decimals="0"
      id="Fact000397"
      unitRef="USD">5000</us-gaap:ProceedsFromRoyaltiesReceived>
    <us-gaap:ProceedsFromRoyaltiesReceived
      contextRef="From2026-01-01to2026-09-30"
      decimals="0"
      id="Fact000398"
      unitRef="USD">15000</us-gaap:ProceedsFromRoyaltiesReceived>
    <us-gaap:SalesCommissionsAndFees
      contextRef="From2026-07-012026-09-30"
      decimals="0"
      id="Fact000399"
      unitRef="USD">1166</us-gaap:SalesCommissionsAndFees>
    <us-gaap:SalesCommissionsAndFees
      contextRef="From2026-01-01to2026-09-30"
      decimals="0"
      id="Fact000400"
      unitRef="USD">1166</us-gaap:SalesCommissionsAndFees>
    <us-gaap:Revenues
      contextRef="From2025-07-012025-09-30"
      decimals="0"
      id="Fact000401"
      unitRef="USD">5000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="From2025-01-012025-09-30"
      decimals="0"
      id="Fact000402"
      unitRef="USD">15000</us-gaap:Revenues>
    <us-gaap:ReceivablesPolicyTextBlock contextRef="From2026-01-01to2026-09-30" id="Fact000404">&lt;p id="xdx_848_eus-gaap--ReceivablesPolicyTextBlock_zDVFwpxL9Vm2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="text-decoration: underline"&gt;Accounts Receivable&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;Accounts receivable is comprised of uncollateralized
customer obligations due under normal trade terms requiring payment within 30 days from the invoice date. The carrying amount of accounts
receivable is reviewed periodically for collectability. If management determines that collection is unlikely, an allowance that reflects
management&#x2019;s best estimate of the amounts that will not be collected is recorded. Management reviews each accounts receivable balance
that exceeds 30 days from the invoice date and, based on an assessment of creditworthiness, estimates the portion, if any, of the balance
that will not be collected. As of September 30, 2026 and December 31, 2025, the Company had determined it was not necessary to recognize
a reserve for doubtful accounts.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

</us-gaap:ReceivablesPolicyTextBlock>
    <us-gaap:IntangibleAssetsFiniteLivedPolicy contextRef="From2026-01-01to2026-09-30" id="Fact000406">&lt;p id="xdx_842_eus-gaap--IntangibleAssetsFiniteLivedPolicy_zVZ1v6RccS04" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="text-decoration: underline"&gt;Intangible assets&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;The Company follows Financial Accounting Standard
Board&#x2019;s (FASB) Codification Topic 350-10 (&#x201c;ASC 350-10&#x201d;), &#x201c;&lt;i&gt;Intangibles &#x2013; Goodwill and Other&lt;/i&gt;&#x201d;.
According to this statement, intangible assets with indefinite lives are no longer subject to amortization, but rather an annual assessment
of impairment by applying a fair-value based test.&#160; Under ASC 350-10, the carrying value of assets are calculated at the lowest level
for which there are identifiable cash flows.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

</us-gaap:IntangibleAssetsFiniteLivedPolicy>
    <us-gaap:ScheduleOfShareBasedCompensationEmployeeStockPurchasePlanActivityTableTextBlock contextRef="From2026-01-01to2026-09-30" id="Fact000408">&lt;p id="xdx_84A_eus-gaap--ScheduleOfShareBasedCompensationEmployeeStockPurchasePlanActivityTableTextBlock_zpaLRa570w4h" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="text-decoration: underline"&gt;Stock-based compensation&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;The Company follows the guidelines in FASB Codification
Topic ASC 718-10 &#x201c;&lt;i&gt;Compensation-Stock Compensation&lt;/i&gt;&#x201d;, which requires the measurement and recognition of compensation
expense for all share-based payment awards made to employees and directors including employee stock options and employee stock purchases
related to an Employee Stock Purchase Plan based on the estimated fair values.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

</us-gaap:ScheduleOfShareBasedCompensationEmployeeStockPurchasePlanActivityTableTextBlock>
    <us-gaap:EarningsPerSharePolicyTextBlock contextRef="From2026-01-01to2026-09-30" id="Fact000410">&lt;p id="xdx_84D_eus-gaap--EarningsPerSharePolicyTextBlock_z1mR7zq5d2q1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="text-decoration: underline"&gt;Earnings (loss) per share&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;Basic loss per share is computed by dividing
net loss available to common stockholders by the weighted-average number of common shares outstanding during the period. Diluted loss
per share includes potentially dilutive common shares only when their inclusion would be dilutive. For the three and nine months ended
September 30, 2026 and 2025, potentially issuable common shares have been excluded because their effect would be anti-dilutive. Accordingly,
basic and diluted loss per share are the same.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;There are&#160;&lt;span id="xdx_905_eus-gaap--IncrementalCommonSharesAttributableToContingentlyIssuableShares_c20260101__20260930_z25OHXNmeLI7"&gt;82,981,326&lt;/span&gt;&#160;additional
shares issuable in connection with outstanding options, warrants, stock payable and convertible debts as of September 30, 2026 The shares
issuable under each instrument is as follows;&#160;&lt;span id="xdx_907_eus-gaap--WeightedAverageNumberOfSharesContingentlyIssuable_c20260101__20260930__us-gaap--StatementEquityComponentsAxis__custom--ConvertibleNotesMember_ze8c2He98Of2"&gt;82,981,326&lt;/span&gt;&#160;shares issuable under convertible notes.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0.45pt 0 6pt; text-align: justify"&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0.45pt 0 6pt; text-align: justify"&gt;&#160;&lt;/p&gt;

</us-gaap:EarningsPerSharePolicyTextBlock>
    <us-gaap:IncrementalCommonSharesAttributableToContingentlyIssuableShares
      contextRef="From2026-01-01to2026-09-30"
      decimals="INF"
      id="Fact000411"
      unitRef="Shares">82981326</us-gaap:IncrementalCommonSharesAttributableToContingentlyIssuableShares>
    <us-gaap:WeightedAverageNumberOfSharesContingentlyIssuable
      contextRef="From2026-01-012026-09-30_custom_ConvertibleNotesMember"
      decimals="INF"
      id="Fact000412"
      unitRef="Shares">82981326</us-gaap:WeightedAverageNumberOfSharesContingentlyIssuable>
    <us-gaap:SegmentReportingPolicyPolicyTextBlock contextRef="From2026-01-01to2026-09-30" id="Fact000414">&lt;p id="xdx_840_eus-gaap--SegmentReportingPolicyPolicyTextBlock_zFEBKp4l2wH4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="text-decoration: underline"&gt;Segment Reporting&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;The Company determined its reporting units
in accordance with ASC 280,&#160;Segment Reporting. Reportable operating segments are determined based on the management approach, as
defined by ASC 280, which is based on the way that the chief operating decision-maker (&#x201c;CODM&#x201d;) organizes segments within the
Company for making operating decisions, assessing performance, and allocating resources. Reportable segments are based on products and
services, geography, legal structure, management structure, or any other manner in which management disaggregates the Company. The Company
operates as a&#160;single&#160;operating and reportable segment.&#160;The Company has identified its&#160;Chief Executive Officer&#160;as
the CODM, who reviews the Company&#x2019;s financial information for purposes of making operating decisions and assessing financial performance.
The net loss is the measure of segment profit (loss) most consistent with U.S. GAAP that is regularly reviewed by the CODM to allocate
resources and assess financial performance.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&#160;&lt;/p&gt;

</us-gaap:SegmentReportingPolicyPolicyTextBlock>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock contextRef="From2026-01-01to2026-09-30" id="Fact000416">&lt;p id="xdx_84C_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_zSx3VA9U28Jj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="text-decoration: underline"&gt;Recently issued accounting pronouncements&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;In July 2025, the FASB issued Accounting Standards
Update 2025-05, Financial Instruments &#x2013; Credit Losses (Topic 326): Measurement of Credit Losses for Accounts Receivable and Contract
Assets ("ASU 2025-05"). ASU 2025-05 provides a practical expedient that all entities can use when estimating expected credit
losses for current accounts receivable and current contract assets arising from transactions accounted for under ASC 606, Revenue from
Contracts with Customers. Under this practical expedient, an entity is allowed to assume that the current conditions it has applied in
determining credit loss allowances for current accounts receivable and current contract assets remain unchanged for the remaining life
of those assets. ASU 2025-05 is effective for fiscal years beginning after December 15, 2025, and interim reporting periods in those years.
Entities that elect the practical expedient and, if applicable, make the accounting policy election are required to apply the amendments
prospectively. The Company has evaluated the impact of ASU 2025-05 on its financial statements and disclosures and has determined that
it does not have a material impact on the financial statements.&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;In November 2025, the FASB issued ASU No. 2025-11,
Interim Reporting (Topic 270): Narrow-Scope Improvements. The amendments clarify and reorganize existing interim reporting guidance, including
the scope of Topic 270 and interim disclosure requirements, and introduce a disclosure principle requiring entities to disclose material
events or changes occurring since the most recent annual reporting period. ASU 2025-11 is effective for interim reporting periods within
annual reporting periods beginning after December 15, 2027. Early adoption is permitted. The Company is currently evaluating the impact
of ASU 2025-11 on its financial statements and related disclosures.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;In December 2025, the FASB issued ASU 2025-12,
Accounting Standards Codification Improvements, which clarifies guidance and makes minor improvements across various topics, including
earnings per share, receivables, revenue, income taxes, and equity. This ASU is effective for annual periods beginning after December
15, 2026, and interim periods within those annual periods, with early adoption permitted. The Company is currently evaluating the impact
of the new guidance on its financial statements and disclosures.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;The Company does not believe that other standards,
which have been issued but are not yet effective, will have a significant impact on its financial statements.&lt;/p&gt;

</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:IntangibleAssetsDisclosureTextBlock contextRef="From2026-01-01to2026-09-30" id="Fact000418">&lt;p id="xdx_801_eus-gaap--IntangibleAssetsDisclosureTextBlock_z3cxpquP4Qe" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;4.&#160;&#160;&#160;&#160;&#160;&#160;&#160;INTANGIBLE AND OTHER
ASSETS&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;Patents and other intangible assets are
capitalized at historical cost and amortized over their estimated useful lives. At September 30, 2026, intangible assets totaled &lt;span id="xdx_906_eus-gaap--IntangibleAssetsCurrent_pp0p0_c20260930_zW9ehROcjVLd"&gt;$84,849&lt;/span&gt;,
net of accumulated amortization of &lt;span id="xdx_903_ecustom--AccumulatedAmortizationOfIntangibleAssets_iI_pp0p0_c20260930_zFZubMNr0eyh"&gt;$222,909&lt;/span&gt;. At December 31, 2025, intangible assets totaled &lt;span id="xdx_90F_eus-gaap--IntangibleAssetsCurrent_iI_pp0p0_c20251231_zdDr8lF1qZLj"&gt;$100,036&lt;/span&gt;, net of accumulated amortization
of &lt;span id="xdx_908_ecustom--AccumulatedAmortizationOfIntangibleAssets_iI_pp0p0_c20251231_zJS9pwZJ3Uwe"&gt;$207,722&lt;/span&gt;. Amortization expense was &lt;span id="xdx_907_eus-gaap--AmortizationOfIntangibleAssets_c20260701__20260930_zkRSETvnXDS8"&gt;$5,184&lt;/span&gt; and &lt;span id="xdx_90C_eus-gaap--AmortizationOfIntangibleAssets_c20250701__20250930_zc9thcZyMEA1"&gt;$5,118&lt;/span&gt; for the three months ended September 30, 2026 and 2025, respectively, and &lt;span id="xdx_903_eus-gaap--AmortizationOfIntangibleAssets_c20260101__20260930_zXXVwZ7XB8S"&gt;$15,187&lt;/span&gt;
and &lt;span id="xdx_905_eus-gaap--AmortizationOfIntangibleAssets_c20250101__20250930_zICAGs10hhbh"&gt;$15,121&lt;/span&gt; for the nine months ended September 30, 2026 and 2025, respectively.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;/p&gt;

</us-gaap:IntangibleAssetsDisclosureTextBlock>
    <us-gaap:IntangibleAssetsCurrent
      contextRef="AsOf2026-09-30"
      decimals="0"
      id="Fact000419"
      unitRef="USD">84849</us-gaap:IntangibleAssetsCurrent>
    <SKVI:AccumulatedAmortizationOfIntangibleAssets
      contextRef="AsOf2026-09-30"
      decimals="0"
      id="Fact000420"
      unitRef="USD">222909</SKVI:AccumulatedAmortizationOfIntangibleAssets>
    <us-gaap:IntangibleAssetsCurrent
      contextRef="AsOf2025-12-31"
      decimals="0"
      id="Fact000421"
      unitRef="USD">100036</us-gaap:IntangibleAssetsCurrent>
    <SKVI:AccumulatedAmortizationOfIntangibleAssets
      contextRef="AsOf2025-12-31"
      decimals="0"
      id="Fact000422"
      unitRef="USD">207722</SKVI:AccumulatedAmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="From2026-07-012026-09-30"
      decimals="0"
      id="Fact000423"
      unitRef="USD">5184</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="From2025-07-012025-09-30"
      decimals="0"
      id="Fact000424"
      unitRef="USD">5118</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="From2026-01-01to2026-09-30"
      decimals="0"
      id="Fact000425"
      unitRef="USD">15187</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="From2025-01-012025-09-30"
      decimals="0"
      id="Fact000426"
      unitRef="USD">15121</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:RelatedPartyTransactionsDisclosureTextBlock contextRef="From2026-01-01to2026-09-30" id="Fact000428">&lt;p id="xdx_801_eus-gaap--RelatedPartyTransactionsDisclosureTextBlock_z2n2FoIf6LF9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;5.&#160;&#160;&#160;&#160;&#160;&#160; &#160;RELATED PARTY TRANSACTIONS&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;Amounts due from a related party were &lt;span id="xdx_90F_ecustom--DueFromRelatedParty_iI_c20260930_zCyGYSCzxdBf"&gt;&lt;span id="xdx_90F_ecustom--DueFromRelatedParty_iI_c20251231_zLYmDyT3BMWb"&gt;$17,592&lt;/span&gt;&lt;/span&gt; at both September 30,
2026 and December 31, 2025. Loans from related parties were &lt;span id="xdx_90C_eus-gaap--OtherLoansPayableCurrent_iI_c20260930_zju5bHIPoZSl"&gt;$135,945&lt;/span&gt; and &lt;span id="xdx_90E_eus-gaap--OtherLoansPayableCurrent_iI_c20251231_z6yq7mZeV3sd"&gt;$45,044&lt;/span&gt;, respectively.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;On January 31, 2023, the Company negotiated
accrued salaries, vacation, and outstanding convertible notes for its two officers. Under the terms of the agreements, all outstanding
notes totaling &lt;span id="xdx_907_eus-gaap--DebtInstrumentFaceAmount_iI_pp0p0_c20230131__us-gaap--RelatedPartyTransactionAxis__custom--ConvertibleNotePayableJan2023Member_zic2C4EyllW5"&gt;$4,220,209&lt;/span&gt;, accrued salaries of &lt;span id="xdx_907_eus-gaap--AccruedSalariesCurrent_iI_pp0p0_c20230131__us-gaap--RelatedPartyTransactionAxis__custom--ConvertibleNotePayableJan2023Member_zebwbzzCdgX8"&gt;$1,062,000&lt;/span&gt;, accrued vacation of &lt;span id="xdx_90B_eus-gaap--AccruedVacationCurrent_iI_pp0p0_c20230131__us-gaap--RelatedPartyTransactionAxis__custom--ConvertibleNotePayableJan2023Member_zFIqgqW3DS33"&gt;$90,193&lt;/span&gt; were converted to promissory notes convertible
into common stock with a warrant feature. The convertible promissory notes are unsecured, due five years from issuance, and bear an interest
rate of &lt;span id="xdx_901_eus-gaap--DebtInstrumentInterestRateDuringPeriod_c20230131__20230131__us-gaap--RelatedPartyTransactionAxis__custom--ConvertibleNotePayableJan2023Member_ze6sDykBOCT2"&gt;10%&lt;/span&gt;. &lt;span id="xdx_905_eus-gaap--DebtInstrumentConvertibleTermsOfConversionFeature_c20230131__20230131__us-gaap--RelatedPartyTransactionAxis__custom--ConvertibleNotePayableJan2023Member_zUd74dRdiFX1"&gt;At the investor&#x2019;s option until the repayment date, the note may be converted to shares of the Company&#x2019;s common
stock at a fixed price of $0.10 per share along with warrants to purchase one share for every two shares issued at the exercise price
of $0.15 per share for three years after the conversion date.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 6pt; text-align: justify"&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 6pt; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" id="xdx_889_eus-gaap--ScheduleOfRelatedPartyTransactionsTableTextBlock_zqj21yzcRMA9" style="font: 12pt Arial, Helvetica, Sans-Serif; margin-left: auto; border-collapse: collapse; width: 50%; margin-right: auto" summary="xdx: Disclosure - 5. RELATED PARTY TRANSACTIONS - Schedule of Convertible Notes Payable Related Party (Details)"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;Convertible Notes Payable consists of the following:&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" id="xdx_49C_20260930_zxSww19gBLUh" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;September 30,&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" id="xdx_497_20261231_z0FoTjW0Szyf" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;December 31,&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;2026&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;2025&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_eus-gaap--ConvertibleNotesPayable_iI_hus-gaap--RelatedPartyTransactionAxis__custom--ConvertibleNotePayableJan2023Member_zDrBpVJP7HL7" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 68%; text-align: left"&gt;Convertible notes payable &#x2014; related parties&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right"&gt;5,372,403&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right"&gt;5,372,403&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_eus-gaap--DebtInstrumentUnamortizedDiscount_iI_hus-gaap--RelatedPartyTransactionAxis__custom--RelatedPartyNotesPayableTotalMember_z0APNbccB0Dl" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt"&gt;Unamortized discount&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0444"&gt;&#x2014;&lt;/span&gt;&#160;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0445"&gt;&#x2014;&lt;/span&gt;&#160;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_eus-gaap--DebtInstrumentUnamortizedDiscountPremiumNet_iI_hus-gaap--RelatedPartyTransactionAxis__custom--RelatedPartyNotesPayableTotalMember_zgdMoYY7jhy1" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt"&gt;Total, net of unamortized discount&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;5,372,403&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;5,372,403&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0.35pt 0pt 0pt"&gt;&#160;&lt;/p&gt;

</us-gaap:RelatedPartyTransactionsDisclosureTextBlock>
    <SKVI:DueFromRelatedParty
      contextRef="AsOf2026-09-30"
      decimals="0"
      id="Fact000429"
      unitRef="USD">17592</SKVI:DueFromRelatedParty>
    <SKVI:DueFromRelatedParty
      contextRef="AsOf2025-12-31"
      decimals="0"
      id="Fact000430"
      unitRef="USD">17592</SKVI:DueFromRelatedParty>
    <us-gaap:OtherLoansPayableCurrent
      contextRef="AsOf2026-09-30"
      decimals="0"
      id="Fact000431"
      unitRef="USD">135945</us-gaap:OtherLoansPayableCurrent>
    <us-gaap:OtherLoansPayableCurrent
      contextRef="AsOf2025-12-31"
      decimals="0"
      id="Fact000432"
      unitRef="USD">45044</us-gaap:OtherLoansPayableCurrent>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="AsOf2023-01-31_custom_ConvertibleNotePayableJan2023Member"
      decimals="0"
      id="Fact000433"
      unitRef="USD">4220209</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:AccruedSalariesCurrent
      contextRef="AsOf2023-01-31_custom_ConvertibleNotePayableJan2023Member"
      decimals="0"
      id="Fact000434"
      unitRef="USD">1062000</us-gaap:AccruedSalariesCurrent>
    <us-gaap:AccruedVacationCurrent
      contextRef="AsOf2023-01-31_custom_ConvertibleNotePayableJan2023Member"
      decimals="0"
      id="Fact000435"
      unitRef="USD">90193</us-gaap:AccruedVacationCurrent>
    <us-gaap:DebtInstrumentInterestRateDuringPeriod
      contextRef="From2023-01-312023-01-31_custom_ConvertibleNotePayableJan2023Member"
      decimals="INF"
      id="Fact000436"
      unitRef="Pure">0.10</us-gaap:DebtInstrumentInterestRateDuringPeriod>
    <us-gaap:DebtInstrumentConvertibleTermsOfConversionFeature
      contextRef="From2023-01-312023-01-31_custom_ConvertibleNotePayableJan2023Member"
      id="Fact000437">At the investor&#x2019;s option until the repayment date, the note may be converted to shares of the Company&#x2019;s common
stock at a fixed price of $0.10 per share along with warrants to purchase one share for every two shares issued at the exercise price
of $0.15 per share for three years after the conversion date.</us-gaap:DebtInstrumentConvertibleTermsOfConversionFeature>
    <us-gaap:ScheduleOfRelatedPartyTransactionsTableTextBlock contextRef="From2026-01-01to2026-09-30" id="Fact000439">&lt;table cellpadding="0" cellspacing="0" id="xdx_889_eus-gaap--ScheduleOfRelatedPartyTransactionsTableTextBlock_zqj21yzcRMA9" style="font: 12pt Arial, Helvetica, Sans-Serif; margin-left: auto; border-collapse: collapse; width: 50%; margin-right: auto" summary="xdx: Disclosure - 5. RELATED PARTY TRANSACTIONS - Schedule of Convertible Notes Payable Related Party (Details)"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;Convertible Notes Payable consists of the following:&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" id="xdx_49C_20260930_zxSww19gBLUh" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;September 30,&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" id="xdx_497_20261231_z0FoTjW0Szyf" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;December 31,&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;2026&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;2025&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_eus-gaap--ConvertibleNotesPayable_iI_hus-gaap--RelatedPartyTransactionAxis__custom--ConvertibleNotePayableJan2023Member_zDrBpVJP7HL7" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 68%; text-align: left"&gt;Convertible notes payable &#x2014; related parties&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right"&gt;5,372,403&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right"&gt;5,372,403&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_eus-gaap--DebtInstrumentUnamortizedDiscount_iI_hus-gaap--RelatedPartyTransactionAxis__custom--RelatedPartyNotesPayableTotalMember_z0APNbccB0Dl" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt"&gt;Unamortized discount&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0444"&gt;&#x2014;&lt;/span&gt;&#160;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0445"&gt;&#x2014;&lt;/span&gt;&#160;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_eus-gaap--DebtInstrumentUnamortizedDiscountPremiumNet_iI_hus-gaap--RelatedPartyTransactionAxis__custom--RelatedPartyNotesPayableTotalMember_zgdMoYY7jhy1" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt"&gt;Total, net of unamortized discount&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;5,372,403&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;5,372,403&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:ScheduleOfRelatedPartyTransactionsTableTextBlock>
    <us-gaap:ConvertibleNotesPayable
      contextRef="AsOf2026-09-30_custom_ConvertibleNotePayableJan2023Member"
      decimals="0"
      id="Fact000441"
      unitRef="USD">5372403</us-gaap:ConvertibleNotesPayable>
    <us-gaap:ConvertibleNotesPayable
      contextRef="AsOf2026-12-31_custom_ConvertibleNotePayableJan2023Member"
      decimals="0"
      id="Fact000442"
      unitRef="USD">5372403</us-gaap:ConvertibleNotesPayable>
    <us-gaap:DebtInstrumentUnamortizedDiscountPremiumNet
      contextRef="AsOf2026-09-30_custom_RelatedPartyNotesPayableTotalMember"
      decimals="0"
      id="Fact000447"
      unitRef="USD">5372403</us-gaap:DebtInstrumentUnamortizedDiscountPremiumNet>
    <us-gaap:DebtInstrumentUnamortizedDiscountPremiumNet
      contextRef="AsOf2026-12-31_custom_RelatedPartyNotesPayableTotalMember"
      decimals="0"
      id="Fact000448"
      unitRef="USD">5372403</us-gaap:DebtInstrumentUnamortizedDiscountPremiumNet>
    <us-gaap:DebtDisclosureTextBlock contextRef="From2026-01-01to2026-09-30" id="Fact000450">&lt;p id="xdx_80C_eus-gaap--DebtDisclosureTextBlock_zxcTSpYOSYmg" style="font: 10pt Times New Roman, Times, Serif; margin: 0.35pt 0 6pt"&gt;6.&#160;&#160;&#160;&#160;&#160;&#160;&#160;NOTES PAYABLE&lt;/p&gt;

&lt;p style="font: 10pt/115% Times New Roman, Times, Serif; margin: 0.15pt 0 6pt; text-align: justify"&gt;On February 7, 2025, the Company issued
a &lt;span id="xdx_901_eus-gaap--DebtInstrumentFaceAmount_iI_c20250207__us-gaap--DebtInstrumentAxis__custom--PromissoryNotePayableFeb7Member_zI1vvcsSJDh2"&gt;$10,000&lt;/span&gt; promissory note payable. The promissory note is unsecured, due &lt;span id="xdx_905_eus-gaap--DebtInstrumentTerm_c20250207__20250207__us-gaap--DebtInstrumentAxis__custom--PromissoryNotePayableFeb7Member_zMakSWmFo1Rl"&gt;one year&lt;/span&gt; from issuance, and bears an interest rate of &lt;span id="xdx_90B_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_c20250207__us-gaap--DebtInstrumentAxis__custom--PromissoryNotePayableFeb7Member_zIOvKGZcizxe"&gt;10%&lt;/span&gt;. &lt;span id="xdx_903_eus-gaap--DebtInstrumentConvertibleTermsOfConversionFeature_c20250207__20250207__us-gaap--DebtInstrumentAxis__custom--PromissoryNotePayableFeb7Member_zm7Nw1nCcNKc"&gt;At
the noteholder&#x2019;s option until the repayment date, the note may be converted to 33,334 shares of the Company&#x2019;s common stock..
As of September 30, 2026, the note has not been paid and is in default As of September 30, 2026, the lender has not issued a formal demand
for payment or notice of default.&lt;/span&gt; The note does not have a default interest rate and the unpaid interest on the defaulted note was &lt;span id="xdx_90C_eus-gaap--InterestPayableCurrent_iI_c20260930__us-gaap--DebtInstrumentAxis__custom--PromissoryNotePayableFeb7Member_zatqIcUEZyK"&gt;$1,644&lt;/span&gt;
and &lt;span id="xdx_900_eus-gaap--InterestPayableCurrent_iI_c20251231__us-gaap--DebtInstrumentAxis__custom--PromissoryNotePayableFeb7Member_zxwlOxtPr2a2"&gt;$896&lt;/span&gt; as of September 30, 2026 and December 31, 2025, respectively.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0.15pt 0 6pt; text-align: justify"&gt;&lt;/p&gt;

</us-gaap:DebtDisclosureTextBlock>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="AsOf2025-02-07_custom_PromissoryNotePayableFeb7Member"
      decimals="0"
      id="Fact000451"
      unitRef="USD">10000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentTerm
      contextRef="From2025-02-072025-02-07_custom_PromissoryNotePayableFeb7Member"
      id="Fact000452">P1Y</us-gaap:DebtInstrumentTerm>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="AsOf2025-02-07_custom_PromissoryNotePayableFeb7Member"
      decimals="INF"
      id="Fact000453"
      unitRef="Pure">0.10</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentConvertibleTermsOfConversionFeature
      contextRef="From2025-02-072025-02-07_custom_PromissoryNotePayableFeb7Member"
      id="Fact000454">At
the noteholder&#x2019;s option until the repayment date, the note may be converted to 33,334 shares of the Company&#x2019;s common stock..
As of September 30, 2026, the note has not been paid and is in default As of September 30, 2026, the lender has not issued a formal demand
for payment or notice of default.</us-gaap:DebtInstrumentConvertibleTermsOfConversionFeature>
    <us-gaap:InterestPayableCurrent
      contextRef="AsOf2026-09-30_custom_PromissoryNotePayableFeb7Member"
      decimals="0"
      id="Fact000455"
      unitRef="USD">1644</us-gaap:InterestPayableCurrent>
    <us-gaap:InterestPayableCurrent
      contextRef="AsOf2025-12-31_custom_PromissoryNotePayableFeb7Member"
      decimals="0"
      id="Fact000456"
      unitRef="USD">896</us-gaap:InterestPayableCurrent>
    <us-gaap:ConvertibleDebtTableTextBlock contextRef="From2026-01-01to2026-09-30" id="Fact000458">&lt;p id="xdx_808_eus-gaap--ConvertibleDebtTableTextBlock_zT2VCNZQm3nk" style="font: 10pt Times New Roman, Times, Serif; margin: 0.15pt 0 6pt"&gt;7.&#160;&#160;&#160;&#160;&#160;&#160;&#160;CONVERTIBLE NOTES
PAYABLE&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 6pt; text-align: justify"&gt;On June 30, 2019, the Company renegotiated accrued
salaries and interest and outstanding convertible notes for a former employee. Under the terms of the agreements, all outstanding notes
totaling &lt;span id="xdx_907_eus-gaap--DebtInstrumentFaceAmount_iI_pp0p0_c20190930__us-gaap--DebtInstrumentAxis__custom--ConvertibleNoteOneRenagotioatedMember_zRbgX3gWxff3"&gt;$224,064&lt;/span&gt;, accrued interest of &lt;span id="xdx_900_eus-gaap--DebtInstrumentIncreaseAccruedInterest_pp0p0_c20190930__20190930__us-gaap--DebtInstrumentAxis__custom--ConvertibleNoteOneRenagotioatedMember_zbcWALAvjkL1"&gt;$119,278&lt;/span&gt;, accrued salaries of &lt;span id="xdx_908_eus-gaap--AccruedSalariesCurrent_iI_pp0p0_c20190930__us-gaap--DebtInstrumentAxis__custom--ConvertibleNoteOneRenagotioatedMember_zbFgPSbut346"&gt;$7,260&lt;/span&gt; and accrued vacation of &lt;span id="xdx_90E_eus-gaap--AccruedVacationCurrent_iI_pp0p0_c20190930__us-gaap--DebtInstrumentAxis__custom--ConvertibleNoteOneRenagotioatedMember_zQfpDuWoFURc"&gt;$1,473&lt;/span&gt; were converted to a promissory
note convertible into common stock with a warrant feature. The convertible promissory note is unsecured, due &lt;span id="xdx_90B_eus-gaap--DebtInstrumentTerm_c20190930__20190930__us-gaap--DebtInstrumentAxis__custom--ConvertibleNoteOneRenagotioatedMember_zFnjjgylkmx5"&gt;five years&lt;/span&gt; from issuance,
and bears an interest rate of &lt;span id="xdx_900_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_c20190930__us-gaap--DebtInstrumentAxis__custom--ConvertibleNoteOneRenagotioatedMember_zykzrmstVxK3"&gt;10%&lt;/span&gt;. &lt;span id="xdx_90E_eus-gaap--DebtInstrumentConvertibleTermsOfConversionFeature_c20190930__20190930__us-gaap--DebtInstrumentAxis__custom--ConvertibleNoteOneRenagotioatedMember_zhk3OlPrQIL7"&gt;At the noteholder&#x2019;s option until the repayment date, the note may be converted to shares of the
Company&#x2019;s common stock at a fixed price of $0.20 per share along with warrants to purchase one share for every two shares issued
at the exercise price of $0.30 per share for three years after the conversion date. As of September 30, 2026, the note has not been paid
and is in default&lt;/span&gt;. As of September 30, 2026 and December 31, 2025, accrued interest associated with this note was &lt;span id="xdx_905_eus-gaap--InterestPayableCurrent_iI_pp0p0_c20260930__us-gaap--DebtInstrumentAxis__custom--ConvertibleNoteOneRenagotioatedMember_zDi7FpPXJMtb"&gt;$127,682&lt;/span&gt; and &lt;span id="xdx_902_eus-gaap--InterestPayableCurrent_iI_pp0p0_c20251231__us-gaap--DebtInstrumentAxis__custom--ConvertibleNoteOneRenagotioatedMember_ze6CFAsBwcaj"&gt;$154,104&lt;/span&gt;,
respectively, which is included in Accrued Interest Payable on the Condensed Consolidated Balance Sheets&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 6pt; text-align: justify"&gt;The Company has determined the value associated
with the beneficial conversion feature in connection with the notes to be &lt;span id="xdx_907_eus-gaap--DebtInstrumentConvertibleBeneficialConversionFeature_pp0p0_c20260101__20260930__us-gaap--DebtInstrumentAxis__custom--ConvertibleNoteOneRenagotioatedMember_zt1g3E2JmSxl"&gt;$152,642&lt;/span&gt; as valued under the intrinsic value method.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" id="xdx_88B_ecustom--ScheduleOfConvertibleNotesPayableTextBlock_zpBb6tDePLYf" style="font: 12pt Arial, Helvetica, Sans-Serif; margin-left: auto; border-collapse: collapse; width: 50%; margin-right: auto" summary="xdx: Disclosure - 7. CONVERTIBLE NOTES PAYABLE - Schedule of Convertible Notes Payable (Details)"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;Convertible Notes Payable consists of the following:&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;September 30,&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;December 31,&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;2026&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;2025&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 68%; text-align: left; padding-bottom: 1pt"&gt;Convertible note payable&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right"&gt;&lt;span id="xdx_903_eus-gaap--ConvertibleNotesPayable_iI_pp0p0_c20260930__us-gaap--DebtInstrumentAxis__custom--ConvertibleNoteOneRenagotioatedMember_zdZe0VR9D0i1"&gt;352,075&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right"&gt;&lt;span id="xdx_906_eus-gaap--ConvertibleNotesPayable_iI_pp0p0_c20251231__us-gaap--DebtInstrumentAxis__custom--ConvertibleNoteOneRenagotioatedMember_zOOaCrzqIZ64"&gt;352,075&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;Total, net of unamortized discount&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span id="xdx_90C_eus-gaap--DebtInstrumentUnamortizedDiscount_iI_pp0p0_c20260930__us-gaap--DebtInstrumentAxis__custom--ConvertibleNoteOneRenagotioatedMember_zCwlEUwMUsfb"&gt;352,075&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span id="xdx_90B_eus-gaap--DebtInstrumentUnamortizedDiscount_iI_pp0p0_c20251231__us-gaap--DebtInstrumentAxis__custom--ConvertibleNoteOneRenagotioatedMember_zYDXA1PHM4gi"&gt;352,075&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt"&gt;&#160;Total Convertible Notes&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span id="xdx_90F_eus-gaap--ConvertibleNotesPayable_pp0p0_c20260930__us-gaap--DebtInstrumentAxis__custom--TotalConvertibleNotesMember_zD8LloTRB648"&gt;352,075&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span id="xdx_902_eus-gaap--ConvertibleNotesPayable_pp0p0_c20251231__us-gaap--DebtInstrumentAxis__custom--TotalConvertibleNotesMember_zSV0Amav5hb1"&gt;352,075&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt"&gt;Current portion:&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span id="xdx_90C_eus-gaap--ConvertibleNotesPayableCurrent_pp0p0_c20260930__us-gaap--DebtInstrumentAxis__custom--TotalConvertibleNotesCurrentMember_zJR5sZFALMYf"&gt;352,075&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span id="xdx_90B_eus-gaap--ConvertibleNotesPayableCurrent_pp0p0_c20251231__us-gaap--DebtInstrumentAxis__custom--TotalConvertibleNotesCurrentMember_zC6OJwlS1us3"&gt;352,075&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt"&gt;Total long-term convertible notes&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span id="xdx_90A_eus-gaap--ConvertibleLongTermNotesPayable_pp0p0_c20260930__us-gaap--DebtInstrumentAxis__custom--TotalLongTermConvertibleNotesCurrentMember_zyMBgQVRNlKa"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0479"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&#160;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span id="xdx_90C_eus-gaap--ConvertibleLongTermNotesPayable_pp0p0_c20251231__us-gaap--DebtInstrumentAxis__custom--TotalLongTermConvertibleNotesCurrentMember_zbxCwOhVRoqk"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0480"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&#160;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&#160;&lt;/p&gt;

</us-gaap:ConvertibleDebtTableTextBlock>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="AsOf2019-09-30_custom_ConvertibleNoteOneRenagotioatedMember"
      decimals="0"
      id="Fact000459"
      unitRef="USD">224064</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentIncreaseAccruedInterest
      contextRef="From2019-09-302019-09-30_custom_ConvertibleNoteOneRenagotioatedMember"
      decimals="0"
      id="Fact000460"
      unitRef="USD">119278</us-gaap:DebtInstrumentIncreaseAccruedInterest>
    <us-gaap:AccruedSalariesCurrent
      contextRef="AsOf2019-09-30_custom_ConvertibleNoteOneRenagotioatedMember"
      decimals="0"
      id="Fact000461"
      unitRef="USD">7260</us-gaap:AccruedSalariesCurrent>
    <us-gaap:AccruedVacationCurrent
      contextRef="AsOf2019-09-30_custom_ConvertibleNoteOneRenagotioatedMember"
      decimals="0"
      id="Fact000462"
      unitRef="USD">1473</us-gaap:AccruedVacationCurrent>
    <us-gaap:DebtInstrumentTerm
      contextRef="From2019-09-302019-09-30_custom_ConvertibleNoteOneRenagotioatedMember"
      id="Fact000463">P5Y</us-gaap:DebtInstrumentTerm>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="AsOf2019-09-30_custom_ConvertibleNoteOneRenagotioatedMember"
      decimals="INF"
      id="Fact000464"
      unitRef="Pure">0.10</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentConvertibleTermsOfConversionFeature
      contextRef="From2019-09-302019-09-30_custom_ConvertibleNoteOneRenagotioatedMember"
      id="Fact000465">At the noteholder&#x2019;s option until the repayment date, the note may be converted to shares of the
Company&#x2019;s common stock at a fixed price of $0.20 per share along with warrants to purchase one share for every two shares issued
at the exercise price of $0.30 per share for three years after the conversion date. As of September 30, 2026, the note has not been paid
and is in default</us-gaap:DebtInstrumentConvertibleTermsOfConversionFeature>
    <us-gaap:InterestPayableCurrent
      contextRef="AsOf2026-09-30_custom_ConvertibleNoteOneRenagotioatedMember"
      decimals="0"
      id="Fact000466"
      unitRef="USD">127682</us-gaap:InterestPayableCurrent>
    <us-gaap:InterestPayableCurrent
      contextRef="AsOf2025-12-31_custom_ConvertibleNoteOneRenagotioatedMember"
      decimals="0"
      id="Fact000467"
      unitRef="USD">154104</us-gaap:InterestPayableCurrent>
    <us-gaap:DebtInstrumentConvertibleBeneficialConversionFeature
      contextRef="From2026-01-012026-09-30_custom_ConvertibleNoteOneRenagotioatedMember"
      decimals="0"
      id="Fact000468"
      unitRef="USD">152642</us-gaap:DebtInstrumentConvertibleBeneficialConversionFeature>
    <SKVI:ScheduleOfConvertibleNotesPayableTextBlock contextRef="From2026-01-01to2026-09-30" id="Fact000470">&lt;table cellpadding="0" cellspacing="0" id="xdx_88B_ecustom--ScheduleOfConvertibleNotesPayableTextBlock_zpBb6tDePLYf" style="font: 12pt Arial, Helvetica, Sans-Serif; margin-left: auto; border-collapse: collapse; width: 50%; margin-right: auto" summary="xdx: Disclosure - 7. CONVERTIBLE NOTES PAYABLE - Schedule of Convertible Notes Payable (Details)"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;Convertible Notes Payable consists of the following:&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;September 30,&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;December 31,&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;2026&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;2025&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 68%; text-align: left; padding-bottom: 1pt"&gt;Convertible note payable&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right"&gt;&lt;span id="xdx_903_eus-gaap--ConvertibleNotesPayable_iI_pp0p0_c20260930__us-gaap--DebtInstrumentAxis__custom--ConvertibleNoteOneRenagotioatedMember_zdZe0VR9D0i1"&gt;352,075&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right"&gt;&lt;span id="xdx_906_eus-gaap--ConvertibleNotesPayable_iI_pp0p0_c20251231__us-gaap--DebtInstrumentAxis__custom--ConvertibleNoteOneRenagotioatedMember_zOOaCrzqIZ64"&gt;352,075&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;Total, net of unamortized discount&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span id="xdx_90C_eus-gaap--DebtInstrumentUnamortizedDiscount_iI_pp0p0_c20260930__us-gaap--DebtInstrumentAxis__custom--ConvertibleNoteOneRenagotioatedMember_zCwlEUwMUsfb"&gt;352,075&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span id="xdx_90B_eus-gaap--DebtInstrumentUnamortizedDiscount_iI_pp0p0_c20251231__us-gaap--DebtInstrumentAxis__custom--ConvertibleNoteOneRenagotioatedMember_zYDXA1PHM4gi"&gt;352,075&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt"&gt;&#160;Total Convertible Notes&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span id="xdx_90F_eus-gaap--ConvertibleNotesPayable_pp0p0_c20260930__us-gaap--DebtInstrumentAxis__custom--TotalConvertibleNotesMember_zD8LloTRB648"&gt;352,075&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span id="xdx_902_eus-gaap--ConvertibleNotesPayable_pp0p0_c20251231__us-gaap--DebtInstrumentAxis__custom--TotalConvertibleNotesMember_zSV0Amav5hb1"&gt;352,075&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt"&gt;Current portion:&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span id="xdx_90C_eus-gaap--ConvertibleNotesPayableCurrent_pp0p0_c20260930__us-gaap--DebtInstrumentAxis__custom--TotalConvertibleNotesCurrentMember_zJR5sZFALMYf"&gt;352,075&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span id="xdx_90B_eus-gaap--ConvertibleNotesPayableCurrent_pp0p0_c20251231__us-gaap--DebtInstrumentAxis__custom--TotalConvertibleNotesCurrentMember_zC6OJwlS1us3"&gt;352,075&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt"&gt;Total long-term convertible notes&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span id="xdx_90A_eus-gaap--ConvertibleLongTermNotesPayable_pp0p0_c20260930__us-gaap--DebtInstrumentAxis__custom--TotalLongTermConvertibleNotesCurrentMember_zyMBgQVRNlKa"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0479"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&#160;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span id="xdx_90C_eus-gaap--ConvertibleLongTermNotesPayable_pp0p0_c20251231__us-gaap--DebtInstrumentAxis__custom--TotalLongTermConvertibleNotesCurrentMember_zbxCwOhVRoqk"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0480"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&#160;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</SKVI:ScheduleOfConvertibleNotesPayableTextBlock>
    <us-gaap:ConvertibleNotesPayable
      contextRef="AsOf2026-09-30_custom_ConvertibleNoteOneRenagotioatedMember"
      decimals="0"
      id="Fact000471"
      unitRef="USD">352075</us-gaap:ConvertibleNotesPayable>
    <us-gaap:ConvertibleNotesPayable
      contextRef="AsOf2025-12-31_custom_ConvertibleNoteOneRenagotioatedMember"
      decimals="0"
      id="Fact000472"
      unitRef="USD">352075</us-gaap:ConvertibleNotesPayable>
    <us-gaap:DebtInstrumentUnamortizedDiscount
      contextRef="AsOf2026-09-30_custom_ConvertibleNoteOneRenagotioatedMember"
      decimals="0"
      id="Fact000473"
      unitRef="USD">352075</us-gaap:DebtInstrumentUnamortizedDiscount>
    <us-gaap:DebtInstrumentUnamortizedDiscount
      contextRef="AsOf2025-12-31_custom_ConvertibleNoteOneRenagotioatedMember"
      decimals="0"
      id="Fact000474"
      unitRef="USD">352075</us-gaap:DebtInstrumentUnamortizedDiscount>
    <us-gaap:ConvertibleNotesPayable
      contextRef="AsOf2026-09-30_custom_TotalConvertibleNotesMember"
      decimals="0"
      id="Fact000475"
      unitRef="USD">352075</us-gaap:ConvertibleNotesPayable>
    <us-gaap:ConvertibleNotesPayable
      contextRef="AsOf2025-12-31_custom_TotalConvertibleNotesMember"
      decimals="0"
      id="Fact000476"
      unitRef="USD">352075</us-gaap:ConvertibleNotesPayable>
    <us-gaap:ConvertibleNotesPayableCurrent
      contextRef="AsOf2026-09-30_custom_TotalConvertibleNotesCurrentMember"
      decimals="0"
      id="Fact000477"
      unitRef="USD">352075</us-gaap:ConvertibleNotesPayableCurrent>
    <us-gaap:ConvertibleNotesPayableCurrent
      contextRef="AsOf2025-12-31_custom_TotalConvertibleNotesCurrentMember"
      decimals="0"
      id="Fact000478"
      unitRef="USD">352075</us-gaap:ConvertibleNotesPayableCurrent>
    <us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock contextRef="From2026-01-01to2026-09-30" id="Fact000482">&lt;p id="xdx_809_eus-gaap--DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock_z2xVrsjQqHK3" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 6pt"&gt;8.&#160;&#160;&#160;&#160;&#160;&#160;&#160;STOCK WARRANTS&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;Following is a summary of stock warrant activity
for the nine months ended September 30, 2026:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" id="xdx_881_eus-gaap--ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_zrhvGKo7v2Tf" style="font: 12pt Arial, Helvetica, Sans-Serif; margin-left: auto; border-collapse: collapse; width: 50%; margin-right: auto" summary="xdx: Disclosure - 8. STOCK WARRANTS - Summary of Stock Warrant Activity (Details)"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;Warrants&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;Weighted average exercise price&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 66%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Outstanding December 31, 2025&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right"&gt;&lt;span id="xdx_909_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20251231__us-gaap--DebtInstrumentAxis__custom--OriginalSharesIssuedMember_zhcq8RalQrli"&gt;189,000&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right"&gt;&lt;span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iI_c20251231__us-gaap--DebtInstrumentAxis__custom--OriginalSharesIssuedMember_zhCLrUrAPH63"&gt;0.60&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_pp0p0_c20260101__20260930__us-gaap--DebtInstrumentAxis__custom--OriginalSharesIssuedMember_zcgpX4bvVAhc"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0487"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&#160;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20260101__20260930__us-gaap--DebtInstrumentAxis__custom--OriginalSharesIssuedMember_z4koLdO9bUca"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0488"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&#160;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Expired &lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations_pp0p0_c20260101__20260930__us-gaap--DebtInstrumentAxis__custom--OriginalSharesIssuedMember_zIEQQbqTUhqb"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0489"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&#160;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_c20260101__20260930__us-gaap--DebtInstrumentAxis__custom--OriginalSharesIssuedMember_zvXnuO3kskRi"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0490"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&#160;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Outstanding September 30, 2026&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span id="xdx_909_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20260930__us-gaap--DebtInstrumentAxis__custom--OriginalSharesIssuedMember_zZCbflkxjs02"&gt;189,000&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iI_c20260930__us-gaap--DebtInstrumentAxis__custom--OriginalSharesIssuedMember_zqMppCry5xyg"&gt;0.60&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 12pt"&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&#160;&lt;/p&gt;

</us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock>
    <us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock contextRef="From2026-01-01to2026-09-30" id="Fact000484">&lt;table cellpadding="0" cellspacing="0" id="xdx_881_eus-gaap--ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_zrhvGKo7v2Tf" style="font: 12pt Arial, Helvetica, Sans-Serif; margin-left: auto; border-collapse: collapse; width: 50%; margin-right: auto" summary="xdx: Disclosure - 8. STOCK WARRANTS - Summary of Stock Warrant Activity (Details)"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;Warrants&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;Weighted average exercise price&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 66%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Outstanding December 31, 2025&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right"&gt;&lt;span id="xdx_909_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20251231__us-gaap--DebtInstrumentAxis__custom--OriginalSharesIssuedMember_zhcq8RalQrli"&gt;189,000&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right"&gt;&lt;span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iI_c20251231__us-gaap--DebtInstrumentAxis__custom--OriginalSharesIssuedMember_zhCLrUrAPH63"&gt;0.60&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_pp0p0_c20260101__20260930__us-gaap--DebtInstrumentAxis__custom--OriginalSharesIssuedMember_zcgpX4bvVAhc"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0487"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&#160;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20260101__20260930__us-gaap--DebtInstrumentAxis__custom--OriginalSharesIssuedMember_z4koLdO9bUca"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0488"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&#160;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Expired &lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations_pp0p0_c20260101__20260930__us-gaap--DebtInstrumentAxis__custom--OriginalSharesIssuedMember_zIEQQbqTUhqb"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0489"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&#160;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_c20260101__20260930__us-gaap--DebtInstrumentAxis__custom--OriginalSharesIssuedMember_zvXnuO3kskRi"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0490"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&#160;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Outstanding September 30, 2026&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span id="xdx_909_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20260930__us-gaap--DebtInstrumentAxis__custom--OriginalSharesIssuedMember_zZCbflkxjs02"&gt;189,000&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iI_c20260930__us-gaap--DebtInstrumentAxis__custom--OriginalSharesIssuedMember_zqMppCry5xyg"&gt;0.60&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="AsOf2025-12-31_custom_OriginalSharesIssuedMember"
      decimals="INF"
      id="Fact000485"
      unitRef="Shares">189000</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="AsOf2025-12-31_custom_OriginalSharesIssuedMember"
      decimals="INF"
      id="Fact000486"
      unitRef="USDPShares">0.60</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="AsOf2026-09-30_custom_OriginalSharesIssuedMember"
      decimals="INF"
      id="Fact000491"
      unitRef="Shares">189000</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="AsOf2026-09-30_custom_OriginalSharesIssuedMember"
      decimals="INF"
      id="Fact000492"
      unitRef="USDPShares">0.60</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock contextRef="From2026-01-01to2026-09-30" id="Fact000494">&lt;p id="xdx_80F_eus-gaap--CommitmentsAndContingenciesDisclosureTextBlock_zKltwWoi0532" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;9.&#160;&#160;&#160; &#160;&#160;COMMITMENTS AND CONTINGENCIES&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;i&gt;License Agreement&lt;/i&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 12pt; text-align: justify"&gt;On October 17, 2019, Skinvisible entered
an Exclusive License Agreement with Quoin pursuant to which Skinvisible granted to Quoin a license to certain patents for the development
of products for commercial sale. In exchange for the license, Quoin agreed to pay to Skinvisible a license fee of&#160;&lt;span id="xdx_90B_eus-gaap--TaxesAndLicenses_pp0p0_c20201017__20201017_zuwF1zgWolq3"&gt;$1,000,000&lt;/span&gt;&#160;and
a royalty percentage on all net sales on the licensed products subject to adjustment in certain situations. The agreement also requires
that Quoin make certain milestone payments to Skinvisible upon achieving regulatory approval milestones for certain drug products.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 12pt; text-align: justify"&gt;The agreement is subject to termination,
if among other things,&#160;&lt;span id="xdx_903_ecustom--PercentPaymentDueToAvoidTermination_c20201017__20201231_zQ0Fz78MHhpa"&gt;50%&lt;/span&gt;&#160;of the license fee is not paid by December 31, 2019 and if the full License Fee is not paid by March
31, 2020. No payments were made by Quoin and the agreement was terminated on December 31, 2019. Both Parties subsequently determined that
they continue to see the value in a partnership and therefore on May 8, 2020 and again on July 31, 2020 the companies agreed to extend
the Exclusive License Agreement, as amended under the same terms to expire on September 30, 2020&#160;&#160;&#160;and on January 27, 2021
the companies agreed to revise the milestone payments due under the agreement and to extend the agreement indefinitely.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 12pt; text-align: justify"&gt;On June 14, 2021, the Company
entered into an amendment to change the terms of the license Fee as shown below:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 12pt; text-align: justify"&gt;As partial consideration for the rights conveyed
by Skinvisible under this Agreement, Licensee agrees to pay to Skinvisible a one-time, non-refundable, non-creditable license issue fee
of one million USD dollars (&lt;span id="xdx_906_eus-gaap--ProceedsFromLicenseFeesReceived_c20220614__20220614__us-gaap--OtherCommitmentsAxis__custom--QuoinMember_zHq1m0Fku7Z4"&gt;$1,000,000&lt;/span&gt;).&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 12pt; text-align: justify"&gt;On February 3, 2020, The Company entered
into a License Agreement with Ovation Science Inc. pursuant to which Skinvisible granted to Ovation Science Inc. a license for the manufacture
and distribution rights to its hand sanitizer product, DermSafe. In exchange for the license, Ovation Science Inc. agreed to pay to Skinvisible
a royalty percentage on all net sales on the licensed products subject to adjustment in certain situations plus a license fee payable
in year 3 of the agreement if it chooses to continue the license. On June 10, 2020, the agreement was further amended to provide additional
assignment rights for its hand sanitizer products in exchange for&#160;&lt;span id="xdx_900_eus-gaap--PaymentsToAcquireManagementContractRights_c20200601__20200610_pp0p0"&gt;$100,000&lt;/span&gt;.&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 12pt; text-align: justify"&gt;On September 18, 2025, the Company signed
a new agreement with Ovation Science. Ovation Science retains exclusive global rights to use Skinvisible&#x2019;s Invisicare&#xae; technology
with cannabinoids for topical and transdermal products, including new formulations with THC-V targeting obesity and metabolic health.
The agreement covers confidential know-how and a pending PCT patent application for transdermal delivery of glucose-controlling agents.&lt;/p&gt;

</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <us-gaap:TaxesAndLicenses
      contextRef="From2020-10-172020-10-17"
      decimals="0"
      id="Fact000495"
      unitRef="USD">1000000</us-gaap:TaxesAndLicenses>
    <SKVI:PercentPaymentDueToAvoidTermination
      contextRef="From2020-10-172020-12-31"
      decimals="INF"
      id="Fact000496"
      unitRef="Pure">0.50</SKVI:PercentPaymentDueToAvoidTermination>
    <us-gaap:ProceedsFromLicenseFeesReceived
      contextRef="From2022-06-142022-06-14_custom_QuoinMember"
      decimals="0"
      id="Fact000497"
      unitRef="USD">1000000</us-gaap:ProceedsFromLicenseFeesReceived>
    <us-gaap:PaymentsToAcquireManagementContractRights
      contextRef="From2020-06-012020-06-10"
      decimals="0"
      id="Fact000498"
      unitRef="USD">100000</us-gaap:PaymentsToAcquireManagementContractRights>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock contextRef="From2026-01-01to2026-09-30" id="Fact000500">&lt;p id="xdx_80F_eus-gaap--StockholdersEquityNoteDisclosureTextBlock_zdMFSjyjxWPk" style="font: 10pt Times New Roman, Times, Serif; margin: 0.25pt 0 6pt"&gt;10.&#160;&#160;&#160;&#160;&#160;&#160;&#160;STOCKHOLDERS&#x2019;
DEFICIT&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 6pt; text-align: justify"&gt;The Company is authorized to issue &lt;span id="xdx_90F_eus-gaap--CommonStockSharesAuthorized_iI_c20260930_zHRscK3K6bsl"&gt;200,000,000&lt;/span&gt;
shares of &lt;span id="xdx_904_eus-gaap--CommonStockParOrStatedValuePerShare_iI_c20260930_zfOxuT50I4e"&gt;$0.001&lt;/span&gt; par value common stock. There were &lt;span id="xdx_909_eus-gaap--CommonStockSharesIssued_iI_c20260930_ztKwq6aQAQs8"&gt;&lt;span id="xdx_90F_eus-gaap--CommonStockSharesOutstanding_iI_c20260930_zsUUTTjHDjmg"&gt;&lt;span id="xdx_90D_eus-gaap--CommonStockSharesOutstanding_iI_c20251231_zeGTAMEkCkUi"&gt;&lt;span id="xdx_905_eus-gaap--CommonStockSharesIssued_iI_c20251231_zlkG1vJFRmMf"&gt;5,403,843&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt; shares issued and outstanding at both September 30, 2026 and December 31,
2025. &lt;span id="xdx_90C_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_do_c20260101__20260930_zB8ceDlkItv3"&gt;No&lt;/span&gt; common shares were issued during the nine months ended September 30, 2026.&lt;/p&gt;

</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="AsOf2026-09-30"
      decimals="INF"
      id="Fact000501"
      unitRef="Shares">200000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="AsOf2026-09-30"
      decimals="INF"
      id="Fact000502"
      unitRef="USDPShares">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesIssued
      contextRef="AsOf2026-09-30"
      decimals="INF"
      id="Fact000503"
      unitRef="Shares">5403843</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="AsOf2026-09-30"
      decimals="INF"
      id="Fact000504"
      unitRef="Shares">5403843</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="AsOf2025-12-31"
      decimals="INF"
      id="Fact000505"
      unitRef="Shares">5403843</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="AsOf2025-12-31"
      decimals="INF"
      id="Fact000506"
      unitRef="Shares">5403843</us-gaap:CommonStockSharesIssued>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2026-01-01to2026-09-30"
      decimals="INF"
      id="Fact000507"
      unitRef="Shares">0</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:SubsequentEventsTextBlock contextRef="From2026-01-01to2026-09-30" id="Fact000509">&lt;p id="xdx_808_eus-gaap--SubsequentEventsTextBlock_z9WIMCy43LRi" style="font: 10pt Times New Roman, Times, Serif; margin: 0.15pt 0 6pt"&gt;11.&#160;&#160;&#160;&#160;&#160;&#160;&#160;SUBSEQUENT EVENTS&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 6pt 6pt"&gt;In accordance with ASC Topic 855-10, the Company has analyzed
its operations subsequent to September 30, 2026 to the date these financial statements were available to be issued and has determined
that it does not have any material subsequent events to disclose in these financial statements.&#160;&#160;&lt;/p&gt;

</us-gaap:SubsequentEventsTextBlock>
</xbrl>
